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ABSTRACT 
Biofabrication of three-dimensional liver cell-embedded tissue constructs for in 
vitro drug metabolism models 
Robert Chao Chang  
Wei Sun, Ph.D 
 
In their normal in vivo matrix milieu, tissues assume complex well-organized three-
dimensional architectures. Therefore, a primary aim in the tissue engineering design 
process is to fabricate an optimal analog of the in vivo scenario. This challenge can be 
addressed by applying emerging layered biofabrication approaches in which the precise 
configuration and composition of cells and bioactive matrix components can recapitulate 
the well-defined three-dimensional biomimetic microenvironments that promote cell-cell 
and cell-matrix interactions. Furthermore, the advent of and refinements in 
microfabricated systems can present physical and chemical cues to cells in a controllable 
and reproducible fashion unrealizable with conventional tissue culture, resulting in high-
fidelity, high-throughput in vitro models. As such, the convergence of layered solid 
freeform fabrication (SFF) technologies along with microfabrication techniques, a three-
dimensional micro-organ device can serve as an in vitro platform for cell culture, drug 
screening, or to elicit further biological insights, particularly for NASA’s interest of a 
flight-suitable high-fidelity microscale platform to study drug metabolism in space and 
planetary environments. A proposed model in this thesis involves the combinatorial setup 
of an automated syringe-based, layered direct cell writing bioprinting process with micro-
patterning techniques to fabricate a microscale in vitro device housing a chamber of 
 xvi 
 
bioprinted three-dimensional cell-encapsulated hydrogel-based tissue constructs in 
defined design patterns that biomimics the cell’s natural microenvironment for enhanced 
performance and functionality. In order to assess the structural formability and biological 
feasibility of such a micro-organ, reproducibly fabricated tissue constructs are 
biologically characterized for both viability and cell-specific function. Another key facet 
of the in vivo microenvironment that is recapitulated with the in vitro system is the 
necessary dynamic perfusion of the three-dimensional microscale liver analog with cells 
probed for their collective drug metabolic function and suitability as a drug metabolism 
model. This thesis details the principles, methods, and engineering science basis that 
undergird the direct cell writing fabrication process development and adaptation of 
microfluidic devices for the creation of a drug screening model, thereby establishing a 
novel drug metabolism study platform for NASA’s interest to adopt a microfluidic 
microanalytical device with an embedded three-dimensional microscale liver tissue 
analog to assess drug pharmacokinetic profiles in planetary environments. 
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CHAPTER 1.  INTRODUCTION AND BACKGROUND 
1.1 Biomanufacturing for Tissue Engineering 
Tissue engineering has classically been defined as the application of the principles 
and methods of engineering and life sciences for the development of biological 
substitutes to restore, maintain, or improve tissue function (Langer et al., 1993). In the 
process of establishing a shift or directional change for the field of tissue science and 
engineering, the 2007 Federal Multi-Agency Strategic Plan, initiated by the NIH, NSF, 
DoD and other Federal agencies, has redefined tissue engineering as “the use of physical, 
chemical, biological, and engineering processes to control and direct the aggregate 
behaviors of cells” as opposed to developing functional tissues for implantation. In 
accordance with this paradigm shift, living cells can be used as basic building blocks to 
manufacture cell-integrated biological structures. Just as central processing units (CPUs) 
form the cores of computers, living cells may form the cores of the next generation of 
biological systems, constructs, and devices. Incidentally, the convergence of engineering 
and the life sciences as the foundation for robust biology-based engineering design and 
analysis has enabled the emergence of a novel interdisciplinary field of biomanufacturing 
or biofabrication (terms that will be used interchangeably in this thesis) which employs 
cells or bioactive factors as nature’s fundamental structural and functional elements from 
which biological models, systems, devices, and products are assembled. Specific 
examples of new broader biomanfacturing applications include the incorporation of cells 
into engineered tissue scaffolds, microfluidic devices, biochips and biosensors, drug 
delivery and toxicity screening platforms, and tissue or organ-on-a-chip devices. 
 2 
 
From a purely mechanistic standpoint, biomanufacturing represents a broad array 
of methods that employ mechanical means to manufacture products that incorporate 
living cells into their systems as well as enable precision multi-scale control of material, 
architecture, and cells (Sun et al., 2007). Successful biofabrication for new broad 
applications, however, must include both an appropriate environment for cell viability 
and function at the microscale level, as well as macroscale-level properties that allow 
sufficient transport of nutrients, provide adequate mechanical properties, and facilitate 
coordination of multicellular processes (Tsang et al., 2004). This in vivo-like milieu, or 
local cellular microenvironment, aims to present biochemical, cellular, and physical 
stimuli that orchestrate cellular fate processes such as proliferation, differentiation, 
migration, and apoptosis. Pivotal in the phenomenological replication of these 
microenvironmental stimuli are the relative composition of cells and biomaterials in a 
tissue engineered scaffold or construct which can be tuned to recapitulate the biophysical 
and biochemical milieus that direct cellular behavior and function (Lutolf et al., 2005). 
Discussed below is an overview of the two general biomanufacturing approaches to 
engineer three-dimensional tissue, i.e. acellular polymer tissue scaffold methods and cell-
integrated tissue construct systems. The sections below will specifically address tissue 
scaffold and cell-integrated tissue construct biofabrication processes involving both cells 
and biomaterials as integral components in the tissue engineered system. 
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1.1.1  Acellular Tissue Scaffold Biofabrication Processes 
The first set of biofabrication processes are classified as ones that exclude cells 
during the initial biomaterial processing phase of scaffold fabrication, but are typically 
seeded on the surface with cells subsequent to the scaffold fabrication and any additional 
post-processing steps for improved scaffold bioactivity. Within the category of acellular 
tissue scaffold biofabrication, the biomaterial processing phase can be classified as being 
heat-based, light mediated, governed by adhesives, or indirectly fabricated with molds. In 
heat-based scaffold biofabrication techniques, the heat energy is applied to a biopolymer, 
thereby elevating the material above its glass transition temperature to facilitate 
sequential fusion of laminated sheets through the application of pressure (Yang et al., 
2002). Currently, these biofabricated laminated sheets exhibit a low void volume that is 
prohibitive of high cell density integration. Another example of heat-based scaffold 
biofabrication is the selective laser sintering (SLS) technique which uses a CO2 laser 
beam to sinter thin layers of powdered polymeric materials. The interaction of the laser 
beam with the powder raises the powder temperature and sintering occurs at just beyond 
the glass transition temperature, thereby causing the particles to fuse together to form a 
solid three-dimensional structure. Application of SLS with formulated suspensions of 
calcium polyphosphate (CPP) and a photocurable monomer as well as other polymer 
blends can lead to the formation of bioresorbable skeletal implants (Porter et al., 2001, 
Tan et al., 2003). The pattern resolution, however, of SLS is limited by the diameter of 
the laser beam to about 400 μm (Yang et al., 2002), and maximum pore size is about 50 
μm due to the powder particle size (Leong et al., 2003). Fused deposition modeling 
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(FDM) is another acellular biofabrication process that combines heat and extrusion 
techniques to create three-dimensional scaffolds layer-by-layer. A nozzle deposits a 
strand of molten plastic or ceramic onto a previously deposited layer of material. Zein et 
al. have implemented this method to produce biodegradable poly(ε-caprolactone) (PCL) 
scaffolds exhibiting various honeycomb geometries with strut widths of 250–700 μm 
(Zein et al., 2002). A variation of the FDM process, the precision extruding deposition 
(PED) system, has been developed and characterized in which the hallmark difference 
between PED and conventional FDM is that the scaffolding material can be directly 
deposited without filament preparation (Shor et al., 2007). Pellet-formed 
polycaprolactone (PCL) is fused by a liquefier temperature provided by two heating 
bands and respective thermal couples and is then extruded by pressure created by a 
turning precision screw. 
1.1.2  Cell-Integrated Tissue Construct Biofabrication Processes 
Acellular tissue scaffolds possess excellent mechanical integrity on the whole, but 
may be difficult to efficiently populate with cells during the cell-seeding phase. In 
contrast, tissue constructs provide high tissue density but may be mechanically unstable 
without a biomaterial support environment. Furthermore, for various tissue engineering 
applications, when cells are seeded onto preformed scaffolds, the result is a non-directed, 
homogenous coating of cells on the scaffold’s surface (Williams et al., 2005, Cortesini, 
2005). Although several cell types can be simultaneously seeded onto scaffolding, there 
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currently exists no way to place different cell types in different parts of the scaffolding, 
much less on a length scale comparable to the heterogeneity found in natural tissue. 
Cell-integrated tissue constructs, particularly those composed of hydrogel 
biopolymers, have therefore become increasingly popular because of their ability to 
provide both structural biomaterial support and a sufficiently high tissue density with 
tissue heterogeneity while maintaining an in vivo-like microenvironment for cells. The 
incorporation of cells in the biomanufacturing process has led to the development of 
various cell printing methods which can be subdivided into structural and conformal cell 
printing (Ringeisen et al., 2006). Both approaches are similar in that the finished printed 
cell construct would be fabricated from the bottom up (i.e., layer-by-layer or cell-by-cell) 
and has heterogeneous cell and biomolecular structure in three dimensions. The 
distinction lies in the fact that structural cell printing requires that the same tool print the 
scaffolding, cells, and biomolecules simultaneously or sequentially, while conformal cell 
printing is a hybrid approach that would print cells and biomolecules on top of thin layers 
of prefabricated scaffolding. Jet-based cell printing methods is an example that has 
shown promise for structural cell printing for simultaneous printing of cells and 
materials, but has been for the most part applied as a conformal printing approach.  
Jet-based printing approaches can be appropriately classified into several distinct 
categories including laser guidance direct writing (LGDW), modified laser-induced 
forward transfer techniques (modified-LIFT), and modified ink jet printers. The 
distinctions between these methods are often related to resolution, print speed, cell 
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throughput, and load volume, which will all have varying levels of relevancy depending 
upon the application (organ, tissue, injury site, etc.) being addressed. The first jet-based 
printing approach is laser guidance direct writing, which utilizes radiation pressure to 
direct particle deposition with micrometer resolution. Odde et al. have demonstrated the 
use of laser-based optical forces to precisely deliver a stream of embryonic chick spinal 
cord cells and ‘write’ them into arbitrary positions on a substrate (Odde et al., 2000, Odde 
et al., 1999). However, if the parameters are not optimized it could lead to further 
problems like fiber clogging because of higher cell density and potential for cell damage 
by using more intense light. The modified laser induced forward transfer technique 
(modified-LIFT) has demonstrated the ability to print patterns of living E. coli (Ringeisen 
et al., 2001) with acceptable cell viability and retained functionality of the printed 
bacteria. This technique has also been successfully implemented to print pluripotent 
embryonal carcinoma cells with near 100% viability and phenotype retention after the 
printing process (Ringeisen et al., 2004). Modified-LIFT possesses the added advantage 
of being an orifice/capillary-free technique to forestall clogging events as well as enable 
orders of magnitude more concentrated cell solutions to be used for printing compared to 
other jet-based technologies. One weakness of the modified-LIST for cell printing is that 
the reproducibility and resolution in prior experiments are low, resulting in a relatively 
small array of pluripotent cells being printed with low resolution and high numbers of 
cells/spot. The final example of jet-based printing techniques is thermal inkjet printing. 
Applying this technique, Mironov et al. have positioned cell aggregates and fused 
together embryonic heart mesenchymal fragments within biocompatible gels of varying 
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chemical and mechanical properties (Mironov et al., 2003). Boland et al. have modified 
thermal ink jet printers to assemble functional three-dimensional cardiac “pseudo-tissue” 
constructs with mechanical properties similar to native tissue (Boland et al., 2007, Boland 
et al., 2006). Maintaining cells in the ink cartridge for long periods of time, however, is 
often difficult and make rapid deposition or replacement/replenishment of the cells, 
biomaterials, or bioactive factors necessary to achieve successful cell printing. 
The cell printing method that is of particular interest in this thesis relates to 
structural cell printing in which cells and polymers can be printed simultaneously to 
result in a cell-embedded tissue construct. While structural cell printing has great 
potential for novel tissue engineered constructs, it is important to note that there are a few 
recent examples in the literature demonstrating that technologies capable of the direct 
assembly of cells and extracellular matrix materials for the construction of functional 
cell-laden three-dimensional tissue constructs with stable structures. The few that are 
documented in literature have managed to adopt technologies that have previously been 
used to print scaffolding materials alone (i.e. without cells). Most of these techniques 
utilize a micro-pen, syringe, or plotter head to print polymer solutions into three-
dimensional assemblies with microscopic structure (Landers et al., 2002, Vozzi et al., 
2003). Moreover, most of these techniques utilize extrusion mechanisms (i.e., pushing 
material through an orifice rather than “jetting” that implies a higher velocity fluid 
stream), and therefore not considered jet-based technologies. Khalil et al. have explored 
the use of a solid freeform based fabrication process where heterogeneous three-
dimensional structures could be developed with cells using a multinozzle dispensing 
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device (Khalil et al., 2005) where the cell viability through the system has been studied 
and reported as well (Chang et al., 2008a). This process, namely the direct cell writing 
(DCW) system is the biofabrication method of choice in this thesis and is discussed 
further in Section 1.4.  
Many processes have been developed in the area of biomanufacturing for the 
development of tissue engineered systems. In this thesis, the scope of the 
biomanufacturing technique implemented is solid freeform fabrication (SFF), which 
collectively refers to a group of technologies capable of manufacturing objects in a layer-
by-layer fashion from a three-dimensional computer design of the object. This layer-by-
layer approach allows the manufacturing of objects not feasible with traditional 
manufacturing methods in which precise control over the macroscopic geometry, internal 
architecture, and interconnectivity is problematic. Computer-aided rapid-prototyping 
technologies have been adapted towards the fabrication of three-dimensional scaffolds 
with precise spatial and temporal control at the macro- and micro-scale levels (Chen et 
al., 2006). This technology aids design and manufacturing customized tissue substitutes 
based on clinical imaging data and computer aided design-based freeform fabrication 
techniques. For example, layered technology that incorporates cells in resorptive 
materials has been implemented for the development of whole organ and/or complex 
functional living systems. Specifically, cell printing methods can be used to deposit cells 
in precise spatial patterns to enhance cell–cell communication, reduce the reliance on cell 
migration to populate the tissue construct, and create artificial tissue structures that more 
closely resemble the in vivo state. Another recent promising approach of 
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biomanufacturing techniques is to furnish biologists with sophisticated in vitro 
physiological models for studying fundamental biological problems. 
1.2 Tissue Engineering In Vitro Physiological Models 
In order to engineer biological tissues in vitro, cultured cells are typically coaxed 
to grow on bioactive porous degradable tissue scaffolds, i.e. temporary synthetic 
extracellular matrices that provide the biological, chemical, and mechanical cues to guide 
the cell’s eventual differentiation and assembly into three-dimensional tissues. While 
regeneration of different tissues and organs for therapeutic applications continues to 
undergo active investigation and development, new applications of tissue engineering for 
designing in vitro physiological models also show great promise. Researchers are 
increasingly identifying a need to engineer tissues amenable for probing the fundamental 
mechanisms of human physiology as well as the evolution of disease processes. In fact, 
Griffith et al. speculates that the greatest impact of tissue engineering in the coming 
decade will be for designing in vitro physiological models for studying disease 
pathogenesis and developing molecular therapeutics (Griffith et al., 2002).  
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Figure 1-1: A microfabricated bioreactor for perfusing three-dimensional liver tissue 
engineered in vitro (Griffith et al., 2002) 
This statement nicely encapsulates a new conceptual framework that could potentially 
find more near-future applicability, i.e. the design and fabrication of in vitro 
physiological models for the purposes of diagnostics, therapeutics, and pathology. These 
physiological surrogates can potentially contribute meaningful advances in prevention, 
diagnosis, and molecular treatment of diseases that are currently considered potential 
targets for tissue engineering.  
The recent development of three specific technologies has greatly facilitated the 
engineering of tissues for in vitro applications: 1) the microfabrication tools that serve to 
both define the cellular microenvironment and enable parallelization of cell-based assays, 
2) tunable hydrogels to create three-dimensional microenvironments; and 3) bioreactors 
to control nutrient transport and fluid shear stress (Khetani et al., 2006). This chapter 
explores previous work along with related technologies for the creation of in vitro 
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microfluidic devices to simulate physiological or pathogenetic human responses to the 
microenvironment. These microtechnology-based processes have several practical 
applications for cells, materials, and tissues cultured on a microscale platform.  These 
include, but are not limited to drug screening, biosensors, and the study of cell-cell or 
cell-matrix interactions in both normal cell biology and disease pathogenesis. 
1.2.1 Drug and Toxicology Screening Models 
One possible near-future application of in vitro physiological models established 
from biology-based engineering analysis is in the area of pharmaceutical drug and 
toxicology screening for drug discovery and development. In these in vitro drug 
screening models, the liver organ is the focus of study due to its primary role in drug 
metabolism. Currently, liver cell-based drug screening is used in pharmaceutical 
development, followed by several rounds of animal testing. A high-fidelity in vitro drug 
metabolism platform, however, can serve as an effective bridge between cell-based 
assays and animal studies by enabling tissue-based drug screening, resulting in more 
accurate assessments of drug action as well as mitigating the use of animals in pre-
clinical drug testing. Additionally, preclinical animal studies are limited for evaluating 
toxicity due to species-specific variation between human and animal liver-specific 
functions, necessitating supplementation of animal data with assays to assess human 
responses (Pritchard et al., 2003). Existing in vitro cell culture models with human liver 
cells have already shown great potential in predicting drug toxicity and metabolism in the 
pharmaceutical industry (Powers et al., 2002). For example, a microfabricated array 
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bioreactor has been designed for perfused three-dimensional liver culture at reported 
near-physiological ranges of perfusate flow rates and fluid shear stresses. Primary rat 
liver cells cultured within these microchannels for a two-week duration undergoes 
rearrangement to form tissue-like structures. Others have reported the modeling of a 
microscale in vitro system to serve as a human surrogate for drug analysis which adheres 
stringently to a physiologically-based pharmacokinetic (PBPK) model in which disparate 
organs are serially connected by channels to comprise a fluid circuit of modular systems. 
This methodology is then applied to mechanistically simulate and predict drug 
biotransformation, distribution, and efficacy in vivo. Therefore, one can imagine the 
design and fabrication of a stamp-sized animal-on-a-chip microfluidic device which, with 
great fidelity, accurately simulates the process of an experimental drug being broken 
down by the metabolizing liver, absorbed by the intestines, and held onto by fat (Ghanem 
et al., 2000, Shuler et al., 1996, Viravaidya et al., 2004).  These models mark the far-
reaching potential for in vitro drug screening technology as well as highlight the current 
availability of crude analogs for the organ functions they're intended to biomimic.  The 
inadequacies of current testing methods include, but are not limited to the lack of a high-
fidelity three-dimensional microenvironment and the ability to reproducibly fabricate 
three-dimensional tissue constructs. The current state-of-the-art for in vitro drug 
toxicology platforms is described in greater detail in Section 1.3.2. 
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1.2.2  Biosensors  
Currently, chemical and biological sensors are delicate, complex devices with 
very limited range and scope that do not accurately predict the human response to 
environmental toxins. Furthermore, molecular sensors are capable of detecting only 
single pathogens or chemicals. The limitations of biological sensors are primarily 
associated with two-dimensional culture on tissue culture plastic which has been a 
mainstay in conventional cell culture by dispersing complex tissues into single cells and 
ignoring higher-order processes. Tissue-based sensors fabricated enlisting the precision 
approaches and processes of microfabrication and layered biofabrication technologies can 
result in cell signaling pathway components as a highly discriminating and sensitive 
detection mechanism for identifying a wide range of pathogens and chemicals. More 
robust sensors based on three-dimensional tissue and/or organ fragments may then be 
used to rapidly detect biological or chemical threats under a variety of conditions and 
scenarios. Tools of biofabrication technology may enable development of increasingly 
sophisticated tissue analogs capable of processing complex environmental information 
and potentially serve as smart sensors in public health surveillance (Bratten et al., 1998, 
Chen et al., 2003, Meyvantssson et al., 2008). 
1.2.3  In Vitro Models of Disease Pathogenesis 
High-throughput technologies based on automation, miniaturization, and 
multiplexing are now feasible for the systematic study of cells. On the one hand, cell-
based models have been the prevailing models in studying cancer and disease 
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pathogenesis verified by testing in animal models of diseases (Borenstein et al., 2007, 
Holmes et al., 2000, Semino et al., 2003). On the other hand, biofabrication technology 
introduces three-dimensional human tissue models for probing basic biological insights 
into cells and tissues as well as understanding human disease processes to curtail the use 
of animals in research. Among the applications are three-dimensional in vitro tissue 
analogs with tissue-embedded chambers that mimic different cancer tissues to elicit 
mechanistic information and further elucidate cell-substrate dynamics in cancer biology.  
For example, the biofabrication of cancer cells patterned with fibrobasts and various 
angiogenic factors can simulate some of the hallmark features of invasion and metastasis 
in cancer, which is often accompanied by fibroblast cell proliferation in the neighboring 
tissues. Another application is in the area of studying the behavior of complex, highly 
specialized cells such as neurons that possess the fundamental constraint of requiring 
other specialized cells for its continued growth and maturation. Substantial progress has 
already been made in two-dimensional patterning of biological substrates for controlled 
cell-material interactions at micrometer scales. A micromechanical device housing three-
dimensional biofabrication tissue constructs, however, can be developed to enable 
manipulation of these cells in a three-dimensional microenvironment to help explain the 
fundamental biological processes cell-cell and cell-matrix signaling and coordination.  
Furthermore, rooted within biofabricated platforms will be measurable surrogates 
or indicators called biomarkers charged with assessing the physiological state of 
condition of the three-dimensional biofabricated tissue constructs. One such application 
is with stem cells, which have naturally been investigated as a candidate cell source for 
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tissue engineering applications. Coordinated alterations in gene expression, and stem cell 
differentiation specifically, however are influenced not only by cell-autonomous 
programs but also by microenvironmental stimuli, which include neighboring cells, 
extracellular matrix, soluble factors, and physical factors. In embryonic development, for 
example, many cell types come into close approximation with one another and 
communicate towards establishing their final identities. Biofabrication methods can serve 
to deploy spatially and temporally specified biomarkers for stem cells on a microscale in 
vitro platform at interim stages of development to identify stem cells and determine their 
state of differentiation. 
1.3 In Vitro Drug Metabolism Models 
1.3.1 NASA’s Interest in an In Vitro Platform for Studying Drug Metabolism in 
Planetary Environments 
NASA’s exploration of space, the solar system, and beyond will invariably 
expose biological systems to hostile space and planetary systems for prolonged periods. 
Novel combinations of stressors and selective pressures will affect all life that has 
originated from this planet. However, cells respond to the environment in specific and 
reproducible ways that are often predictive of functional consequences, and, as 
bioreporters in space, can provide an assessment of combinatorial outcomes from 
numerous simultaneous environmental factors. Moreover, multiple events may be probed 
at the organism, organ, tissue, cellular, genetic, and molecular level, enabling a 
comprehensive assessment of potential synergistic stressor effects.  
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NASA’s interest in microfluidic technology originates in the enabling microscale 
capabilities to significantly influence the design and implementation of modern 
bioanalytical systems due to the fact that these miniaturized devices can integrate 
multiple chemical processing and handling steps in a much more efficient way than 
conventional instruments. This results in several advantages including reduced reagent 
volumes, fully automated biochemical analyses, parallel processing capabilities for 
system redundancy, and remote operation. These properties greatly enhance the value of 
microfluidic systems to NASA for use on small aircrafts with limited resources for long 
duration manned and unmanned environmental monitoring missions. 
The conducted collaborative research herein between NASA-JSC, Kansas State 
University, and Drexel University, is specifically intended to explore the development 
and study of a space flight-suitable in vitro three-dimensional Microfluidic 
Microanalytical Micro-organ Device (3MD) for simulation of human response to drug 
administrations and toxic chemical exposure under microgravity and space environments. 
A schematic of the multi-chamber drug metabolism device is shown in Figure 1-2 below 
in which a non-fluorescent pro-drug is fed into the microfluidic circuit towards the first 
liver chamber where the drug is metabolized (either activated or deactivated) to a 
metabolite that can subsequently exert an effect on a downstream epithelial target tissue. 
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Figure 1-2: Schematic of multi-compartment micro-organ device for drug metabolism 
studies 
1.3.2 The Biopharmaceutical Industry and the Drug Development Process 
In recent years, the research and development process in the biopharmaceutical 
industry sector has become increasingly complex and costly. Clinical trials in particular 
have become increasingly complicated for a variety of reasons, including difficulty 
recruiting and retaining volunteers, increasingly complex diseases being studied, and 
more testing against comparator drugs. As the complexity of the process has increased, so 
have the associated costs. The trend towards increasing costs is shown in Figure 1-3. 
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Figure 1-3: Cost to develop an approved drug for the marketplace 
On average today, companies spend an estimated $1.3 billion on R&D over a 10-15 year 
span for each approved drug (Dimasi et al., 2003, Dimasi et al., 2007). Approximately 
half of this investment takes place during the preclinical testing phases, while the balance 
is invested during clinical studies. A diagram of the R&D process from drug discovery to 
FDA approval is depicted in Figure 1-4.  
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Figure 1-4: The R&D process from drug discovery to approval 
Once a compound has demonstrated some activity against the drug target, it undergoes 
extensive testing in the lab, both in test tubes and animal models. Years of preclinical 
testing must establish that the candidate medicine is likely to be safe and effective in 
humans before clinical testing can begin. 
Now, since the liver organ is primarily responsible for drug metabolism and 
detoxification in the human body, the pre-clinical stage of the drug testing and 
development process typically includes a panel of in vitro liver toxicology screens 
followed by extensive studies in live animals for predicting the pharmacodynamic and 
pharmacokinetic properties of a new chemical entity or drug. Current methods for 
evaluating the acute and chronic toxicity of a substance are performed primarily on live 
animals in which chronic liver toxicity studies are performed over long periods from 
several months to several years by controlled daily injection of toxic substances that may 
induce suffering in the animal. The justification for conducting comprehensive liver 
toxicity studies is the liver’s continuous exposure to an array of exogenous substances or 
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insults. Therefore, a prominent function of the liver is to control the biotransformation 
and the elimination of toxic waste substances from the body. The liver receives dual 
blood supply from 1) the gastrointestinal tract via the portal vein and 2) the systemic 
circulation via the hepatic artery, thereby leaving the liver uniquely susceptible to both 
acute and chronic injuries. In fact, idiosyncratic drug-induced liver toxicity is the leading 
cause of post-market drug warnings and withdrawals, despite extensive animal testing 
(Kaplowitz et al., 2005). This can be explained by the inherent complexity of the body 
along with a significant number of uncontrolled parameters related to the animal model, 
resulting in challenges in interpreting in vivo analysis that takes into account various 
undefined or unknown effects, including but not limited to individual variations in the 
human drug pharmacokinetic response related to genetics, pathophysiology, and 
environmental factors. The need for an appropriate and predictive in vitro preclinical 
drug evaluation is highlighted by the fact that around 50% of the drugs found to be 
responsible for liver injury during clinical trials do not render any liver damage in animal 
experiments (Venkatesh et al., 2000). Consequently, there is a need for an in vitro 
modality to predict both acute toxicity and chronic toxicity owing to repeated exposures 
to low doses as well as mixtures of compounds in the liver. To address this unmet need 
for a predictive drug screen, several pertinent in vitro physio-toxicological models have 
been proposed (Baudoin et al., 2006). However chronic toxicity studies using in vitro 
conventional culture on a two-dimensional monolayer are limited in the fact that studies 
can only be evaluated over a few days as these cellular models cannot preserve liver-
specific function for prolonged periods, but rather undergo cell de-differentiation. 
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However, nearly 90% of the lead candidates identified by existing in vitro screens fail to 
become drugs resulting in an unmet need for systems that are more predictive of the in 
vivo metabolism and toxicity profile of the drug for longer duration studies (Sivaraman et 
al., 2005). Thus, the challenge of and pre-requisite for a good predictive screen is the 
preservation of liver functions in culture over long time periods in order to build adequate 
models for drug screening and development. 
In configuring predictive in vitro liver systems, hepatocytes (i.e. the primary 
parenchymal cellular component in the liver) are the primary cell type or common choice 
for constructing drug screening assays. Cytochrome P450 (CYP) represents the family or 
complex of enzymes primarily responsible for drug detoxification in the liver. Among the 
CYP families, CYP1, CYP2, and CYP3 family are the ones involved in drug metabolism. 
The CYP catalyzed oxidation-reduction drug reactions results in the addition of OH, NH2 
or COOH groups to the molecules (i.e. Phase I of biotransformation). These 
transformations increase the solubility of the molecules for its future elimination. 
However, in some cases, CYPs also activates prodrugs or procarcinogens which become 
toxic through this reaction. Since drug biotransformation that involves a set of Phase I 
(cytochrome P450 mediated) and Phase II enzyme reactions can affect the overall 
therapeutic and toxic profile of a drug, several pertinent in vitro models have been 
proposed to understand and mimic in vivo drug biotransformation as detailed in the 
following section on the state-of-the-art of in vitro drug screening assays (Baudoin et al., 
2006).   
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1.3.3 Current Status of Drug Screening Assays 
In vitro models of the liver have been used as screens for making quantitative and 
qualitative measurements of pharmacodynamic and pharmacokinetic properties of the 
candidate drug during the pre-clinical screening stage of the drug development process as 
well as for bioartificial liver support systems (Davila et al. 1998, Brandon et al., 2003). 
However, the development of in vitro liver cell models in extended culture that stably 
express functional properties of the in vivo liver from which the cells are derived 
represents a monumental challenge for predicting toxicity of drugs or chemicals. A 
number of in vitro liver culture formats have been developed to replicate the in vivo liver 
biotransformation functions. Among these culture systems are isolated perfused livers, 
liver tissue slices, primary hepatocyte cultures, immortalized cell lines, and intracellular 
or subcellular fractions such as microsomes. The advantages of the isolated perfused liver 
model is that it closest resembles the native in vivo liver cell polarity with a three-
dimensional histology and three-dimensional architectural organization with a close 
approximation of in vivo drug metabolizing enzyme expression with a full complement of 
the drug metabolic equipment. The limitations of the isolated perfused liver model is that 
it is difficulty in sourcing human liver organs, lack of high-throughput capability, and 
liver function is only transiently preserved (Lee et al., 2008, Brouwer et al. 1996). Next, 
the advantages of an in vitro model implementing liver tissue slices include the in vivo 
like liver architecture and expression that typify the isolated perfused liver model along 
with improved high-throughput capability and availability over that of whole liver 
organs. The limitations associated with liver tissue slices include short-term liver-specific 
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function and viability in addition to the frequent occurrence of necrotic cells at the edges 
of the liver slice, i.e. diffusional barriers (Catania et al. 2007, LeCluyse et al., 2001, 
Lerche-Langrand et al., 2000). Now, many in vitro drug metabolism model systems to 
date have implemented liver cells or hepatocytes since hepatocytes represent 70-80% of 
the total liver cell population and express most xenobiotic metabolizing enzyme 
activities. For primary hepatocyte cultures, the advantages include ease of use and 
differentiated function can be maintained in many short-term and some long-term 
cultures. The deficiencies of primary hepatocyte culture formats include the loss of drug 
metabolizing enzyme activity in long-term culture and often require specially tailored 
media supplementation in culture due to the propensity for changes in the fidelity of drug 
metabolic activity after removal of hepatocytes from the liver organ (LeCluyse et al., 
2005, Cross et al., 2000). In the case of immortalized cell lines, the key strengths include 
unlimited availability with prolonged subculture and drug metabolic functions have been 
maintained by researchers. The limitations of cell lines include the lack of diversity in the 
in vivo phenotype and a narrow spectrum of gene expression (Yu et al. 2001).  Finally, an 
example of a subcellular source for in vitro liver systems are the liver microsomes which 
offer the advantage of high-throughput capability and whose Phase I enzyme expression 
can be maintained. The limitations include the lack of diversity in liver-specific functions 
due to the absence of dynamic gene expression and the intact cellular machinery required 
for toxicity testing. Of the culture format alternatives, primary human hepatocytes 
represent the most pertinent high-throughput model for in vitro drug metabolism since 
they express most of CYP isoforms, but demonstrate limited growth activity and early 
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phenotypic alterations symptomatic of mammalian primary cultures. Immortalized liver 
cell lines, however, primarily originate in liver tumors and therefore endowed with an 
indefinite capacity for proliferation. While liver cell line do lack a variable and 
substantial set of liver-specific functions including the major CYP related-enzyme 
activities, human hepatoma (e.g. HepG2) cell lines do contain some of the CYP isoforms 
essential for in vitro drug metabolism studies and affect the overall therapeutic and toxic 
profile of a drug. While a variety of modifications to conventional cell culture methods 
have been proposed to foster retention of hepatocyte function at desired in vivo levels, 
including the use of co-culture formats to simulate heterotypic interactions, this thesis 
will strictly use the HepG2 liver cell line as the most suitable cell source or culture format 
due to ease of handling and propagation.  
A major challenge with cell-based in vitro culture formats for drug metabolism 
studies is that liver cells rapidly lose liver-specific functions when maintained under 
standard in vitro static two-dimensional cell culture conditions (Lecluyse et al., 1996, 
Baker et al., 2001). Therefore, many approaches have been proposed to preserve the liver 
functions for extended times in order to construct adequate long-term in vitro drug 
metabolism study platforms. One approach for the enhancement of liver-specific function 
such as drug metabolization is the judicious selection of an appropriate biomaterial with 
key extracellular matrix components amenable for optimal culture on single-layer 
basement membrane gels (Lecluyse et al., 1996, Shuetz et al., 1988, Ben-Ze’ev et al., 
1988). Specifically, Shuetz et al. observed that compared to rat hepatocyte culture on type 
I collagen, incubation of hepatocytes on the reconstituted basement membrane Matrigel 
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results in the maintenance of hepatocyte morphology and adherence and liver-specific 
gene expression for more than 1 week in vitro. Moreover, Ben-Ze’ev et al. showed that 
rat hepatocytes cultured on Matrigel resulted in the formation of spherical cellular 
aggregates that exhibit low DNA, cytoskeletal mRNA, and protein synthesis while 
simultaneously exhibiting elevated liver-specific mRNAs and albumin production, 
thereby conforming closely to the in vivo liver gene expression program. Additionally, 
modulating the hepatocyte microenvironment by overlaying collagen gels on top of 
monolayer cultures, i.e. collagen gel sandwiches, has managed to upregulate liver-
specific function sustained over a month period (Dunn et al., 1989, Chen et al., 1998). 
Specifically, Dunn et al. cultured rat hepatocytes in a collagen sandwich system and 
maintained normal morphology and physiological rates of liver-specific function for at 
least 42 days. The same hepatocytes cultured on a single layer of collage gel ceased to 
express liver-specific function within 1 week, only to recover function with an overlay of 
a second collagen gel layer. Chen et al. conducted a long-term primary human hepatocyte 
culture by first maintaining cells on a Matrigel matrix and then transferring to a collagen 
sandwich gel. These cells maintained the liver-specific ability to secrete albumin, alpha-
fetoprotein, and transferring up to a maximum of 5 months. In an additional functional 
enhancement, Kono et al. demonstrated upregulation of cytochrome P450 activity with 
the presence of structures resembling in vivo bile caniliculi that exist on the apical side of 
liver plates (Kono et al., 1997). In order to study the effects of intercellular contacts 
between hepatocytes on liver-specific function, Abu-Absi et al. cultured hepatocytes to 
form solid multicellular spheroids possessing tight junctions and micro-villi lined 
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channels containing bile (Wu et al, 1999, Abu-Absi et al. 2002, Koide et al., 1990, 
Peshwa et al. 1996). This configuration resulted in the maintenance of liver-specific 
functions overall several weeks compared to the non-aggregated counterpart, including 
higher albumin secretion, urea excretion, and cytochrome p450 activity. Another 
approach utilized to enhance liver-specific function in vitro is to recapitulate the 
heterotypic interactions with co-culture configurations with either non-liver-derived 
stromal-like cell types on static or perfused two-dimensional substrates (Bhatia et al., 
1997, Donato et al., 1990, Gugen-Guillouzo et al., 1983, Khetani et al., 2004, Gebhardt et 
al., 1996). Bhatia et al., for example, has co-cultivated hepatocytes with fibroblasts using 
a versatile technique for micropatterning based on existing strategies for surface 
modification with aminosilanes linked to biomolecules and facile manipulation of the 
serum content of cell culture media, and shown this culture format to support enhanced 
liver functions in vitro whereby the fibroblasts modulate and stabilize liver function 
through direct intercellular contacts. Therefore, while the functional relevance of 
extracellular matrix, cell morphology, and the orchestration of homotypic and heterotypic 
intercellular contacts is well-accepted, microfabrication tools are only recently emerging 
to manipulate these tools in vitro. Another approach adopted by Mitaka et al. is the 
development of culture conditions to promote liver characteristics, specifically the 
addition of exogenous compounds using nutrient-rich medium with 2% DMSO induces 
proliferating hepatoytes to recover the hepatic differentiated functions with maintenance 
of function for an extended period (Mitaka et al., 1994). In another modification, culture 
of cells in a variety of bioreactors employs hydrodynamic flows and fluid handling that 
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take into account the dynamic effects and transport of media rich in oxygen and nutrients 
(Bader et al., 1994, De Bartolo et al., 2001, Surapaneni et al., 1997). Nussler et al. 
designed a hollow fiber bioreactor culture model in order to confer improved metabolic 
capacity of hepatocytes in vitro over a two-week study period (Nussler et al., 2001).  
Modifications of traditional culture formats allows in vitro liver systems to 
capture some aspects of in vivo liver physiology, including the appropriate cell 
interactions, aspects of liver architecture and microenvironment, and fluid flow stresses 
required to achieve the full spectrum of drug metabolic function. Nevertheless, the 
primary attributable metabolic or biotransformational function of the liver can as yet be 
mimic desired in vivo levels, prompting continued development of novel culture methods 
and high-fidelity drug testing platforms. In order to recreate the in vivo microenvironment 
in an in vitro liver tissue culture system, it is vitally important to firstly understand the 
structure and physiology of the liver which confer upon it the distinction as the ideal drug 
biotransformation organ. Specifically, in the in vivo milieu, owing to the close spatial 
configuration of cells and matrix, the cellular phenotype and viability of the liver cell is 
influenced by the environment, either by paracrine effects of secreted soluble factors, or 
by direct cell-matrix and cell-cell interactions, and mechanico-chemical stimuli arising 
from local perfusion flows. 
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1.4 Development of a Novel Direct Cell Writing Biomanufacturing System 
A proprietary multi-nozzle direct cell writing (DCW) system has been developed 
at Drexel University for the freeform construction of biopolymer based three-dimensional 
tissue scaffolds and cell-embedded tissue constructs (Khalil et al., 2005, Khalil et al., 
2007, Chang et al., 2008). The schematic of the direct cell writing system configuration is 
shown in Figure 1-5.  
 
Figure 1-5: Schematic of the direct cell writing system 
This direct cell writing process is designed to operate at cell-friendly conditions of room 
temperature and low pressure conditions to deposit multiple cell types and bioactive 
factors in controlled amounts with precise spatial positioning to form pre-designed, cell-
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embedded tissue constructs with easily adaptable patterned architectures. These unique 
features of the cell printing system enable the direct printing of cells and biological 
substances along with the carrying material. Other layered manufacturing methods utilize 
harsh solvents, high pressures or temperatures, or post-processing methods that are not 
suitable for working with bioactive materials. Compared to most reported cell dispensing 
systems that are mostly limited to a single nozzle for cell dispensing or limited to cell 
printing, this multi-nozzle direct cell writing system as shown in Figure 1-6 enables the 
simultaneous deposition of cells, growth factors, and scaffold materials to form 
heterogeneous or functional gradient tissue structures.  
 
Figure 1-6: Direct cell writing system with multinozzle capability 
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An information pipeline of the direct cell writing system for freeform fabrication of tissue 
constructs is presented in Figure 1-7. 
 
Figure 1-7: Process information pipeline for the direct cell writing biofabrication process 
As shown in the figure, the data processing software processes the computer-aided design 
(CAD) model of the tissue construct and converts it into a layered two-dimensional 
process tool path. The motion control system is driven by a layered manufacturing 
technique. The material delivery system supplies various nozzles with the appropriate 
biopolymer or biological factor. The system consists of an air pressure supply both 
positive and negative, a material container or reservoir, and a material delivery tube. Each 
nozzle system has its independent process parameters and material properties adjusted as 
required such as the air pressure and biopolymer concentration. The system implements 
multiple nozzles with different types and sizes, thus enabling the deposition of specified 
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hydrogels with different viscosities for fabricating three-dimensional tissue constructs. 
Four types of the nozzles can be adapted to the direct cell writing system: solenoid-
actuated nozzles, piezoelectric glass capillary nozzles, pneumatic syringe nozzles, and 
spray nozzles, with deposited diameter size ranges varying from 30 μm to 500 μm. The 
system can continuously extrude continuous hydrogel strands, or form hydrogels in single 
droplets with picoliter volumes.  
  In the development of the direct cell writing system, several micro-nozzle systems 
have been investigated to evaluate their performances and feasibility to deposit 
biopolymer solutions for tissue engineered constructs. The specific biopolymer 
deposition process performed in this study implements a pneumatic microvalve which is 
a typical mechanical valve that opens and closes the valve via an applied air pressure 
regulated by a controller detailed in Figure 1-8.  
 
(a)                                                                (b) 
Figure 1-8: Pneumatic microvalve nozzle for direct cell writing. (a) Schematic diagram 
of the pneumatic microvalve; (b) Schematic diagram of the air control per cycle 
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The system is capable of operating in extrusion or droplet mode. In extrusion mode, the 
controller applies pressure to open the valve by lifting the piston against the spring that 
lifts the needle from the needle seat. The biopolymer material is then extruded from the 
nozzle tip under an applied pressure that is adjusted through the material delivery system. 
The extrusion is complete when the controller closes the valve by placing the needle back 
to the needle seat. The pneumatic microvalve can perform in droplet mode by repeating 
the continuous mode in a cyclic manner. Multiple pneumatic valves can be 
simultaneously operated for performing heterogeneous deposition in the development of 
the three-dimensional tissue constructs. 
As a biomanufacturing technology, the direct cell writing system has been 
developed for the biofabrication of cell-integrated tissue constructs. This novel 
biomanufacturing technique is amenable for the demonstration of a predetermined 
engineering design of tissue constructs. The DCW system implements a sub-system to 
generate the two-dimensional toolpath from a solid scaffold model and to control the 
motion of the deposition nozzle, namely the two-dimensional toolpath generation and 
XYZ positioning system displayed in Figure 1-9 along with the motion controller 
software.  
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Figure 1-9: Schematic of XYZ-axis positioning system with nozzle pressure controller 
The XYZ positioning system is a numerical control (NC) code driven system which 
drives the deposition nozzles according to the generated toolpath through motion 
controller software. The motion controlling component is a proprietarily developed 
software system used to control the speed, location, and movement of XYZ positioning 
system based on the generated toolpath.   
Specifically, the toolpath generation starts with the conversion of a computer 
aided designed scaffold solid model into stereolithography (STL) format which is a 
common surface representation format in which the boundary of the object is formed 
from triangles. Following the format conversion, using commercially available 
Quickslice software, this STL model is divided into layers, and subsequently each layer is 
 34 
 
translated into a toolpath, a single line which doubles back on itself repeatedly to form 
parallel paths, or multiple tool paths if the layer is discontinuous. Figure 1-10 illustrates 
the steps for the scaffold design toolpath generation.  
 
Figure 1-10: Division of STL model into layered toolpath 
The variables predetermined by the toolpath are the pore size which is the distance 
between two parallel lines of the toolpath and the layer height. The pore size is the 
primary determinant of the porosity, and the layer height represents the diameter of the 
strut being deposited, which is itself contingent upon nozzle size, material deposition 
condition, and the lateral speed of the positioning system. 
1.5 Research Objectives and Approach 
This thesis rests on the hypothesis that the higher order functions of the liver, in 
particular the drug metabolic capacity, may be optimally simulated in an in vitro culture 
if critical facets of the in vivo microenvironment are recapitulated. These include the in 
vivo three-dimensional microenvironment and shear-mediated microfluidic perfusion 
flows.  Therefore, the objective of the conducted research is aimed at the design, 
modeling, fabrication, and characterization of a three dimensional microfluidic 
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microanalytical micro-organ (3MD).  The scope of the research includes the achievement 
of high-throughput reproducible fabrication of bioprinted tissue constructs, maintenance 
of tissue structural integrity, direct integration with the microfluidic platform, and 
enhancement of cell viability and control of cellular-level differentiation and tissue-level 
function. The applied rapid prototyping technology presented is a structurally and 
biologically viable syringe-based direct cell writing (DCW) process for layer-by-layer 
fabrication of three-dimensional cell-encapsulated hydrogel-based tissue constructs. More 
specifically, the objective is to develop a viable direct cell bioprinting process for 
fabrication of reproducible three-dimensional cell-encapsulated alginate-based tissue 
engineered constructs within three-dimensional tissue chambers as a drug metabolism 
model.  This strategy can be further exploited to fabricate various three-dimensional in 
vitro tissue analogs consisting of an array of channels with tissue-embedded chambers 
representing different mammalian tissues for a multitude of applications for clinical 
pharmaceutical screening efficacy and toxicity for the agent of interest. 
The conducted collaborative research between NASA-JSC, Kansas State 
University, and Drexel University, supported through NASA USRA subcontract #09940-
008, is intended to explore the development and study of an in vitro three-dimensional 
microfluidic microanalytical micro-organ Device (3MD) for simulation of human 
response to drug administrations and toxic chemical exposure under microgravity and 
space environments. By fabricating a three-dimensional in vitro tissue analog consisting 
of an array of channels with tissue-embedded chambers, one can selectively biomimic 
different mammalian tissues for a multitude of applications, foremost among them liver 
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tissue for experimental pharmaceutical screening of drug efficacy and toxicity.  The 
objective of research conducted at Drexel University is aimed at the achievement of high-
throughput reproducible fabrication of bioprinted three-dimensional tissue constructs into 
microscale tissue chambers, maintenance of structural integrity, and integration with a 
microfluidic platform, and enhancement of cell viability and cell phenotype retention. 
Specifically, specific objectives of this thesis are:   
1) to develop the methodology for combining biofabrication with microfabrication to 
create a microfluidic/microanalytical device for drug metabolism study  
2) to develop an optimized biomanufacturing process for reproducible cell-
encapsulated three-dimensional structures towards the study of drug metabolism 
3) to optimize material/culture conditions for liver cell viability and cell-specific 
function towards the study of drug metabolism 
4) to study the underlying scientific and engineering basis of micro-organ drug 
metabolic conversion as a function of microfluidic flow pattern design and flow 
conditions 
1.6  Thesis Outline 
Chapter 1 introduces the field of biomanufacturing and reviews some of the novel 
biomanufacturing techniques that encompass a broad range of physical, chemical, 
biological, and engineering processes, with various applications in tissue science and 
engineering. Specific emphasis is placed on solid freeform fabrication techniques for 
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layered biomanufacturing of tissue scaffolds or constructs. Chapter 1 also discusses the 
application of tissue engineering to in vitro physiological models such as biosensors, 
biological phenomena and diseases processes, with a particular emphasis on in vitro drug 
metabolism models.  NASA’s interest in such in vitro drug metabolism models in space 
is discussed along with a review on the advantages and limitations of existing platforms 
for evaluating the behavior of new chemical entities in drug development. This 
establishes the need for a novel biofabrication system, i.e. the development of the direct 
cell writing system for reproducibly manufacturing high-fidelity, high-throughput, three-
dimensional microscale cell-embedded tissue constructs for the application of drug 
metabolism studies. Chapter 1 concludes with the research objectives of this dissertation 
along with the approaches adopted. Chapter 2 explains the design of the three-
dimensional micro-organ and microfluidic platform, initiated by a discussion on the key 
facets of the liver microenvironment that will serve as guiding principles for the design of 
the micro-organ device for drug metabolism studies. The chapter then proposes specific 
biopolymer materials as candidates for bioprinting liver micro-organs. Chapter 3 is 
focused on the biomanufacturing aspects of applying layered fabrication along with 
microfabrication methods for complete unit assembly of the micro-organ device. Next, 
Chapter 4 establishes science and engineering basis for the micro-organ device by 
numeric modeling of fluid dynamics and mass transfer effects of a continuously perfusing 
drug/media flow through a channel pattern defined by a bioprinted three-dimensional 
liver micro-organ that biomimicks the in vivo liver sinusoidal capillary architecture. Prior 
to conducting drug perfusion flow experimentation, Chapter 5 and Chapter 6 presents 
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prefatory data to serve as guideposts for the selection of appropriate parameters, 
materials, and culture conditions to optimize the drug conversion downstream dynamic 
flow studies of bioprinted tissue constructs. Chapter 5 specifically examines the effect of 
the solid freeform fabrication based direct cell writing process, focusing on specific key 
process parameters, on the viability of liver cells within alginate.  Chapter 6, on the other 
hand summarizes preliminary static culture experiments on bioprinted tissue constructs to 
1) validate the need for a three-dimensional microenvironment and 2) elicit the material 
parameters and nutrient media requirements favorable for optimal drug conversion. 
Finally, Chapter 7 summarizes the research conducted, concluding remarks, an 
enumerates the research contributions to the scientific and engineering community, and 
some suggestions for future work that can either further elaborate and extrapolate my 
research findings or adopt similar approaches and techniques for novel investigation. 
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CHAPTER 2.  DESIGN OF THE THREE-DIMENSIONAL LIVER MICRO-
ORGAN AND MICROFLUIDIC PLATFORM 
2.1 Capturing Key Facets of the Liver Microenvironment in an In Vitro System 
2.1.1 The In Vivo Liver Hepatic Architecture and Circulation Parameters 
Figure 2-1 details the liver with a dual afferent blood supply where (1) the portal vein 
delivers nutrient rich, relatively deoxygenated blood from the pancreas and intestines to 
the metabolically-active liver, and (2) the hepatic artery which delivers oxygenated blood 
after branching off of the celiac axis of aorta that shares cascade arrangement with 
intestinal vasculature.  
 
 
 
Figure 2-1: The dual afferent blood supply to the liver organ 
Small portal venules receive blood from venous outflow of the GI tract by way of portal 
veins. Portal blood is collected from organs of the GI system and associated glands. The 
liver can modify the portal blood before it leaves for the systemic circulation. Collected 
blood flows into hepatic sinusoids (capillary-like) that lie among the hepatocytes and then 
into the central vein. The hepatocytes surround a central vein, so they are exposed 
continuously to portal venous blood. The central vein can in turn empty into the hepatic 
vein and then into the abdominal vena cava. Hepatic arterioles supply lobular tissue 
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directly with oxygenated blood or may empty into the hepatic sinusoids. The feature 
dimensions of the liver are shown below in Figure 2-2.  
        
 
Figure 2-2: Feature dimensions of the liver architecture 
This schematic of the liver microenvironment shows the spatial arrangement of cell types 
allowing both chemical as well as mechanical cues from each other and extracellular 
matrix facilitated by the flow through of blood. The venous sinusoids are lined by typical 
endothelial cells and Kupffer cells (macrophages, reticuloendothelial cells). The Kupffer 
cells can phagocytize bacteria and foreign matter in the blood. The endothelial cells have 
large pores. Between the rows of hepatocytes and the endothelial cells are narrow spaces, 
the spaces of Disse. The millions of spaces of Disse are connected with lymphatic vessels 
in the lobular septa. Excess fluid from the sinusoids passes through the pores of the 
2mm
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200um 
Multiple Cell Architecture 
Sinusoids in contact with 
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endothelial cells lining the sinusoids, into the space of Disse, and is removed through the 
lymphatics. Even large plasma proteins can diffuse through the endothelial pores into the 
space of Disse.  
About 30% of the resting cardiac output flows through the liver. Blood flows 
from the portal vein to the hepatic sinusoids at a rate of 1100 ml/min, and about 300 
ml/min of blood flows to the sinusoids from the hepatic artery. Therefore, 1400 to 1500 
ml/min total blood leaves the liver via the hepatic vein. The resistance to blood flow 
through the liver sinusoids is usually low. Pressure in the portal vein entering the liver is 
about 9 mm/ Hg and pressure from the hepatic vein entering the vena cava is about 0 mm 
/Hg. 
2.1.2 The In Vivo Functional Liver Unit Structural Organization 
There are two main competing views of the structural organization of the fundamental 
functional unit of the liver—the lobule and the acinus as shown in Figure 2-3 below.  
 
Figure 2-3: Competing views of hepatic structural organization 
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Both models possess a hexagonal tissue structure with the portal triads at the vertices and 
the central vein at the centroid. In Kiernan’s proposed lobule model, the blood passes into 
the periphery from the digestive tract via the portal triad, traverses the sinusoid, and then 
exits via the central vein as depicted in Figure 2-4. 
                                                                        
Figure 2-4: Liver lobule model 
The portal triad is comprised of three vessels: the hepatic artery bringing oxygenated 
blood from the heart, the portal vein carrying enriched blood from the intestine, and the 
bile duct which drains bile from individual bile ducts. These inputs and outputs branch 
into complex tree structures, which supply and drain the entire liver. 
 Rappaport proposed the acinar model in 1954 based on the observation that as 
blood passes through the sinusoids, oxygen content and dissolved solutes are altered at 
different positions in the sinusoids by the hepatocytes which have contacted it. 
Consequently, the cell types in the liver represent a heterogeneous population of cells 
whose function differs relative to the composition of contacted blood. Therefore, the 
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acinus is subdivided into three zones graded by the depletion of oxygen and other 
metabolites in adjacent red blood cells as they travel the length of the sinusoid toward the 
central vein as shown in Figure 2-5. 
                    
Figure 2-5: Liver acinus model 
The hepatic acinus is diamond-shaped with borders defined by lines that connect the 
central veins of two neighboring classical lobules with two adjacent periportal spaces, 
functionally defined as the region that is irrigated by the terminal distributing branch of 
the portal vein that runs around the periphery of the lobule. Based on their proximity to 
the distributing veins, the cells in the hepatic acinus are subdivided into three zones I-III 
with the incoming blood passing through zone I first and continuing into zone II and III. 
The gradient for substances coming in with the blood (nutrients, oxygen, toxic 
substances) thus define functional differences among the hepatocytes in the different 
zones. Isolating a single sinusoid shows the fundamental unit of liver structure: a set of 
thin hepatocyte plates, called the acinus, strung between the portal triad and the hepatic 
venule.  
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 These two models of the liver, though seemingly disparate, provide the 
foundation for current physiological models. Further research should result in a more 
definitive model for the architecture of the basic functional unit of the liver, but for the 
purposes of this research the liver will be viewed as a heterogeneous hexagonal tissue, 
which is a simplification and an incorporation of both theories. 
 Additionally the liver has an equally intricate organization on the cellular level 
that may be required to be replicated to achieve proper function. The acinus is organized 
in a perfused, spongelike, capillary bed structure, composed primarily of mature 
hepatocyte plates of a single cell thickness, known as the parenchyma. These plates have 
an apical domain which forms bile canalicular networks in the secretion of bile 
components and metabolites of xenobiotics, and a basal domain which interacts with 
ECM and participates in cell signaling. These hepatic plates are lined by fenestrated 
endothelial cells, which create a physical and chemical shield between the sinusoid and 
the hepatic plate. The region between the endothelium and the hepatic plate, known as the 
Space of Disse, is traversed by stellate cells, or the resident liver fibroblasts. Interspersed 
in the sinusoid are kupffer cells, a specialized form of macrophage. Fluid flows through 
two paths: the bulk travels “down” the acinus from the portal region to the central vein; 
hepatocytes also form ducts known as bile canaliculi that transport bile retrograde or “up” 
to the bile duct in the portal triad. These ducts are separated from the rest of the tissue by 
tight junctions between neighboring hepatocytes in a similar fashion to that of the 
digestive system.  
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 Most in vitro experiments with adherent human cells are performed in 
conventional monolayer two-dimensional cultures in which cells are plated or seeded 
onto homogeneous polystyrene plastic substrates treated to simulate cell attachment and 
spreading. Depending on their type, cells either grow directly on the plastic, secrete ECM 
components that coat the plastic to facilitate cell adhesion, or require pre-coating of the 
plastic with ECM. Standard two-dimensional culture conditions are poor mimics of the 
cellular environment in an animal: soluble growth factors are present at abnormally high 
concentrations, three-dimensional cues are largely absent, oxygen tension is too high and 
cell-cell interactions are rarely organized. Therefore, conventional cell culture disperses 
tissues into single cells while neglecting higher-order processes. Attempts have been 
made to overcome these problems using organ culture and various laboratory-scale 
bioreactors, but microscale systems provide much more effective means of controlling 
cell environment in vitro. Particularly promising are various artificial organ systems in 
which multiple cell types are grown together under conditions that mimic normal three-
dimensional environmental and circulatory cues. Microfluidics has the additional 
advantage of being capable of creating mechanical strain, through shear, in the 
physiological range. A microscale circulation-type bioreactor system enables the 
simultaneous evaluation of multiple specimens. 
2.2 Material Considerations - Hydrogels 
 In the design of the three-dimensional liver micro-organ in this work, hydrogel 
biopolymers are selected as the material to effectively encapsulate hepatocytes within a 
three-dimensional matrix microenvironment. Hydrogels are either synthetic or naturally-
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derived hydrophilic polymer networks that swell in the presence of water. Among 
numerous applications, hydrogels have been used for cell encapsulation since their 
mechanical properties resemble that of native soft tissues while intrinsically exhibiting 
high permeability to oxygen, nutrients, and other water-soluble metabolites. Additionally, 
hydrogels exhibit mechanical and chemical properties that may be engineered via 
addition of functional groups or modulation of degradation rates to manifest other 
desirable characteristics. As a result of this customizability, hydrogels have been widely 
used in tissue engineering and drug delivery applications. 
 Hydrogels have many different functions in the field of tissue engineering. They 
are primarly applied as delivery vehicles for bioactive molecules, and as three-
dimensional structures that organize cells and present stimuli to direct the formation of a 
desired tissue. First of all, bioactive molecules are delivered from hydrogel scaffolds in a 
variety of applications including promotion of angiogenesis and encapsulation of 
secretory cells (Drury et al., 2003). Finally, hydrogel scaffolds are being applied to 
transplant cells and to engineer nearly every tissue in the body, including cartilage, bone, 
and smooth muscle. 
In traditional tissue engineering, cells are seeded upon the surface of porous 
scaffolds and are induced to migrate and populate the inner regions. In many cases, cells 
do not evenly seed within the scaffold because of the large distances they must migrate in 
order to populate the scaffolds. Attempts have been made to homogenize cell seeding 
distribution through, for example, the application of centrifugal force to surface-seeded 
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scaffolds or the continuous perfusion of scaffolds with cell suspended solutions. These 
techniques require cumbersome equipment and have not been demonstrated for 
microscale scaffold constructs. In contrast, the techniques described here exploit the 
encapsulation of cells within hydrogel materials. The advantage of cell encapsulation to 
cell seeding in porous scaffolds for tissue engineering is the homogeneity of cell 
distribution that may be achieved. In cell encapsulation applications, cells are embedded 
within hydrogels by suspending the cell in a liquid hydrogel precursor, followed by 
crosslinking of the polymer network. In this way, uniformly-distributed hydrogel-
encapsulated cells are required to migrate shorter distances during the subsequent 
remodeling of cells into tissue. 
2.2.1 Alginate as Tissue Matrix Material 
Alginates are naturally derived polysaccharides that are derived primarily from 
seaweed. They are composed of (1-4) linked β-D- mannuronic acid (M units) and α-L-
guluronic acid (G units) monomers along the polymer backbone. The M and G units may 
vary in ratio depending on the alginate source. The alginate molecule is considered to be 
a block copolymer with regions of M and G units that both have carboxylic groups. The 
carboxylic groups are capable of forming salt formations such as sodium alginate, where 
the sodium monovalent ions are attached ionically to the carboxylic groups as shown in 
Figure 2-6. 
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Figure 2-6: Chemical structure of sodium alginate biopolymer 
Sodium alginate is soluble in water and when dissolved forms a viscous solution that 
could vary depending on the concentration and molecular weight of the biopolymer. In 
the presence of divalent calcium ions, sodium alginate solution is crosslinked ionically 
between chains to form a hydrogel. The calcium ions exchange with sodium ions on the 
G blocks and bind together adjacent chains that precipitate the gelation of alginate. It has 
been reported that ionically crosslinked alginates lose mechanical properties in vitro over 
time. It is presumed that this phenomenon occurs due to an outward flux of crosslinking 
ions to the surrounding medium (Shoichet et al., 1996). A study by Wang et al. is 
conducted to investigate the ability of rat bone marrow cells to proliferate and 
differentiate on alginates of differing composition and purity. It is found that high purity 
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and high G-type alginate retained 27% of its initial strength after 12 days in culture 
(Wang et al., 2003). The formation of alginate gels may take place in two known 
methods; diffusion setting and internal gelation. In the first, alginate solution such as 
sodium alginate is deposited directly in to a reservoir of divalent ions such as calcium 
chloride. The gelation process takes place as the calcium ions gel the outer most layer of 
sodium alginate and then diffuse into the core of the material to gel internally. In the later 
method, the process is vice versa where the calcium chloride solution is introduced into a 
reservoir of sodium alginate. The gelation in this method begins at the outer surface of 
the calcium chloride solution and then proceeds into the sodium alginate outer body. Both 
gelation methods have been used for various applications. 
 Tissue engineering biomaterials should fulfill several preconditions such as high 
level of biocompatibility and biodegradability. These are also required to have low 
degree of cytotoxicity, high affinity to biological surfaces, mechanical stability to the 
construct, and serve as a guide for three-dimensional tissue regeneration. Alginate is a 
nontoxic immunologically inert hydrogel and therefore has been widely used for scaffold 
material for immobilization of enzymes or cells for bioreactors, and also for tissue 
engineering. Alginate has been mainly utilized in tissue engineering as a delivery vehicle 
or supporting matrix cell via encapsulation techniques. Alginate-based 
microencapsulation is currently a favored approach because animal studies and small 
scale clinical trials have shown that the requirements for long-term immunoisolation and 
simultaneous maintenance of transplant function can most likely be fulfilled by this 
hydrogel (Leinfelder et al., 2003). Many groups have demonstrated various techniques 
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for producing alginate beads of controlled dimensions for cell encapsulation. The use of 
alginate in cell encapsulation requires the gel to be of high purity to exploit cytotoxic and 
apoptosis-inducing impurities. The purification and sterilization processes are time-
consuming labor work that is accomplished by filtration techniques. Alginate degradation 
is not carried out by mammalian cell digestion, instead, divalent calcium ions slowly 
diffused out of the hydrogel allowing alginate molecules to be excreted in the urine. 
Alginate has been used extensively in the culturing of chondrocytes, as well as for 
hepatocytes and Schwann cells for nerve regeneration. 
One of the drawbacks of alginate is that there is no specific interaction between 
mammalian cells alginate gel. That is, alginate does not directly provide active 
attachment sites for anchorage-dependent cells. In addition, a negative charge balance 
exists in alginate gels that inhibit protein absorption due to electrostatic repulsion. For 
this reason, many studies have modified alginate with peptides for cell adhesion. The 
carboxylic acid on alginate makes it attractive for modification such as in peptide 
attachments. For example, in a study by Kreeger et al., the roles of peptide density in 
alginate on murine granulose cell adhesion, morphology, and steroid secretion are 
conducted (Kreeger et al., 2003). Their results show that murine granusola cells attached 
and spread on the modified surfaces with morphologies specific to the peptide identity 
and density.  
Several studies have emphasized the importance of maintaining hepatocyte cell 
lines in culture conditions that impose a three-dimensional architecture on cells, and have 
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highlighted the advantage of alginate encapsulation (Khalil et al., 2005). Compared with 
other matrix support systems or monolayer cultures, alginate encapsulated cells 
maintained significantly higher expression of differentiated function, and for many liver-
specific products the synthetic capacity per cell performance was equivalent to that seen 
in vivo. Specifically, compared with cells in monolayer culture, alginate-encapsulated 
cells have an approximately 10-fold higher expression of a panel of protein synthetic and 
secretory functions, and an expression of cytochrome P450-mediated functions. 
2.2.2 Matrigel as Tissue Matrix Material 
Much effort in tissue engineering has focused on controlling the microscale 
environment of three-dimensional matrices. Recently, Matrigel has been a biomaterial of 
interest in certain applications for this purpose. Norman et al. studied the effects of 
discrete microscale structures (microrods) on cell proliferation in three-deimensional 
Matrigel gels (Norman, et al., 2008). Experimentally, 100 µm x 15 µm x 15µm (length x 
height x width) microrods fabricated out of SU-8 are incorporated into Matrigel seeded 
with fibroblasts. The results demonstrate that the three-dimensional microrod-Matrigel 
composite gels inhibit the proliferation of fibroblasts compared to cells seeded in 
Matrigel alone. Furthermore, it is determined that the suspended microrods can regulate 
cell proliferation in a dose-dependent manner. Advancements in this type of research will 
enable the development of a biocompatible system in which long term cell growth and 
proliferation can be modulated in three-dimensional cultures.  
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 Another recent tissue engineering advancement by Wong and colleagues has 
utilized Matrigel for adjustable three-dimensional cellular microenvironments in vitro 
using microfluidics (Wong et al., 2008). More specifically, they have developed a method 
that allows controlled spatial distribution (patterning) of multiple types of cells within 
three-dimensional Matrigel gels along with the controlled application of gradients of 
soluble factors, such as cytokines, across the Matrigel constructs. Their technique uses 
laminar flow to divide a microchannel into multiple subchannels separated by microslabs 
of hydrogel, making it possible to design model systems to study cellular communication 
mediated by the diffusion of soluble factors within three-dimensional matrices. The 
authors suggests that their technique would be especially useful for studying cells such as 
those of the immune system, which are often weakly adherent and difficult to position 
precisely with standard cell culture systems.  
 In tissue engineering, Matrigel has also been used as a scaffold biomaterial. 
However, it is commonly believed that Matrigel “with the maximum thinkable 
likelihood, will never be granted (FDA) approval,” and therefore, “is not a suitable option 
in human tissue engineering” (Polykandriotis et al., 2008). Despite this, the potential 
benefits of Matrigel as a scaffold/ECM material have continued to drive its use in the 
development of many tissue engineering organs in vitro. Matrigel has shown promise as a 
scaffold for vascular graft development (Abilez et al., 2006). Under pulsatile conditions, 
undifferentiated mouse embryonic stem cells (mESC) have been grown in three-
dimensional Matrigel matrices.  Recent efforts in the reconstruction of engineered uterine 
tissues (EUTs) have also utilized Matrigel. Epithelial cells were mixed with stromal cells 
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in a 1:2 collagen:Matrigel gel to form an endometrial layer on top of a smooth muscle 
layer (Lu et al., 2008). The epithelial cells showed self assembly in the EUTs, and the 
reconstructed EUTs demonstrated the ability to support the development of embryos. 
Three-dimensional pulmonary tissue constructs in vitro have also shown positive results 
using Matrigel. Three-dimensional FPC constructs were created using Matrigel and 
synthetic polymer scaffolds of poly-lactic-co-glycolic acid (PLGA) and poly-L-lactic-
acid (PLLA) fabricated into porous foams and nanofibrous matrices (Modrinos et al., 
2006). The experimental results demonstrated that the three-dimensional Matrigel 
constructs contained alveolar forming units with proper cellular ultrastructure, gene 
expression, and gene product. Furthermore, the addition of specific growth factors 
induced the formation of branching and sacculated epithelial structures similar to distal 
lung architecture in vivo. Matrigel matrices have also been explored as a method for 
tissue engineering cartilage implants using embryonic stem cells (Jukes et al., 2008).   
Advancements in tissue engineering nerve cells have also benefited from the use 
of Matrigel. Laminin, an important component of Matrigel, promotes the attachment and 
growth of neurites in vitro, and seems a logical choice for nerve regeneration. Madison et 
al have shown that laminin-rich Matrigel enhanced sciatic nerve regeneration through 
biodegradeable nerve guide channels (Madison et al., 1985). Furthermore, Kjavin et al. 
has shown that laminin-containing gels, such as Matrigel, enhanced regeneration of 
mouse sciatic nerves within silicon tubular prosthesis compared to similar silicon tubes 
filled with collagen gel (Kjavin et al., 1991). Experimentally, when presented with two-
dimensional PDL-adsorbed surfaces, three-dimensional Matrigel, and grooved 
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topography, neuritis preferred extending into the three-dimensional gel layers of Matrigel 
rather than along the PDL surfaces of the grooved topographical substrates (Li et al., 
2008). The mechanical and dimensional properties of the matrix materials have been 
shown to be of great importance to the characteristics of the developed neurons. 
Experimentally, the stiffer three-dimensional matrix of collagen supported longer neurons 
than two-dimensional collagen matrices. However, softer three-dimensional Matrigel 
matrices supported shorter neurons than two-dimensional Matrigel matrices.  
A recent effort in tissue engineering skeletal muscle tissue networks has used 
innovative techniques in controllable gel architecture and reproducible fabrication (Bian 
et al., 2009). This reproducible techniques involves injecting a cell/gel mixture composed 
of fibrinogen, collagen type 1, Matrigel at 10% (v/v) , C2C12 myoblasts, and primary rat 
skeletal myoblasts into a microfabricated PDMS mold. The research group claims that 
this approach produces relatively large skeletal muscle tissue networks made of viable, 
densely packed, highly aligned, cross-striated, and spontaneously contractile myofibers. 
For liver tissue applications, Babensee et al. studied hepatoma cells (HepG2), an 
anchorage-dependent cell line, and microencapsulated them in a HEMA-MMA 
polyacrylate membrane to which the cells do not adhere (Babensee et al., 1992). This 
environment is altered by the coencapsulation of Matrigel, a reconstituted extracellular 
matrix derived from the Engelbreth-Holm-Swarm (EHS) mouse tumor basement 
membrane, to provide sites for cell attachment. The effect on the cells of these two 
capsule microenvironments during a 2-week in vitro culture period is assessed by 
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examining the spatial arrangement, morphology, and viability of the cells using light 
microscopy and scanning electron microscopy (SEM). In the absence of Matrigel, cells in 
HEMA-MMA capsules are found to form aggregates in intracapsular pockets with central 
necrosis occurring at day 7 in large aggregates. The coencapsulation of HepG2 cells with 
Matrigel, resulted in an initially uniform distribution of essentially individual cells with 
aggregates appearing later within the Matrigel. Many cells within these capsules had 
remained viable when examined up to day 14 with only limited cellular necrosis, 
implying a favorable environment for microencapsulated HepG2 cells. 
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CHAPTER 3.  BIOFABRICATION OF THE THREE-DIMENSIONAL LIVER 
MICRO-ORGAN AND MICROFLUIDICS  
There has been keen interest recently in microscale systems for cell culture because 
microsystems offer capabilities either unavailable or difficult to implement in 
conventional macroscale cell culture systems. For example, microscale tools enable more 
precise control of the microenvironment by allowing precise control of direct cell-cell 
interactions, cell-matrix interactions, soluble factors, and mechanical forces (Thomas et 
al., 2002, Chen et al., 1997, McBeath et al. 2004). Microscale cell cultures also support 
higher-throughput experimentation along with enabling integration onto a microfluidic 
chip for dynamic profiling assays. Specifically, the unique capability microfluidic 
technologies to miniaturize assays and increase experimental throughput have generated 
significant interest in the drug discovery and development domain.  
This chapter therefore explores the development for the design and biofabrication of 
an in vitro three-dimensional microfluidic microanalytical micro-organ device (3MD) for 
simulation of the physiological human response to drug administrations and toxic 
chemical exposure. The applied solid freeform fabrication technology is a viable 
bioprinting freeform fabrication process for layer-by-layer extrusion of three-dimensional 
cell-encapsulated hydrogel-based tissue constructs. By fabricating a three-dimensional in 
vitro tissue analog consisting of an array of channels with tissue-embedded chambers, 
one can selectively biomimic different mammalian tissues for a multitude of applications 
for pharmaceutical screening of drug efficacy and toxicity. The research conducted is 
aimed at the achievement of high-throughput reproducible fabrication of bioprinted tissue 
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constructs and three-dimensional organ chambers, maintenance of structural integrity and 
direct integration with the microfluidic platform, and enhancement of cell viability and 
display of cellular-level differentiation and tissue-level function. More specifically, the 
objective is to develop a viable direct cell writing process for fabrication of reproducible 
three-dimensional cell-encapsulated alginate-based tissue engineered constructs within 
three-dimensional liver tissue chambers as a drug metabolism model. An overview of this 
biofabricated drug metabolism platform is show in schematic in Figure 3-1. 
 
Figure 3-1: Overview of the biofabricated drug metabolism platform 
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3.1  Development of the Direct Cell Writing System for Freeform Fabrication of 
Cell-Laden Liver Tissue Constructs 
In Chapter 1, the development of a proprietary multi-nozzle direct cell writing 
system is detailed for freeform fabricating biopolymer based three-dimensional tissue 
scaffolds and cell-embedded tissue constructs (Khalil et al., 2005, Khalil et al., 2007, 
Chang et al., 2008). However, it is the convergence of solid freeform fabrication (SFF) 
along with the enabling tools of microfluidics that is providing investigators with the 
emerging opportunity to biomanufacture and study tissues in vitro with heretofore unseen 
levels of sophistication. To give a sense of the length scales here, microfabrication 
techniques have traditionally been used in integrated microelectronic circuits. Now these 
techniques can be adopted to create microscale platforms that integrate cell, tissues, or 
whole animals onto a chip as shown in Figure 3-2.  
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Figure 3-2: Schematic for the integration of biological tissues or whole animals onto a 
microfabricated device 
Specifically, we are studying the liver, which is the primary organ responsible for the 
metabolic activities of the body. Therefore, modifications of these traditional techniques 
have been primed for these disciplines to work in concert for novel applications of tissue 
engineered liver constructs as shown in Figure 3-3. 
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Figure 3-3:  Convergence of layer-by-layer biofabrication and microfabrication 
techniques 
The direct cell writing process is integrated with a microfluidic device to fabricate three-
dimensional tissue/organ constructs/chambers in Figure 3-4, as opposed to producing 
two-dimensional cell monolayers.  
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Figure 3-4:  Overview of direct cell writing three-dimensional micro-organ approach 
Biological studies reveal the unstable cellular phenotype and reduced tissue-specific gene 
expression with conventional monolayer in vitro culture techniques. A three-dimensional 
tissue model will, in contrast, foster improved retention of cell-specific function. 
Furthermore, direct cell deposition of encapsulated cells offers tighter control over the 
spatial distribution of cells, allowing one to assemble high cell density or co-culture 
multiple cell types within a three-dimensional construct. This can create tissue structures 
that more closely resemble the in vivo state. Cell-cell communication either from direct 
contact or paracrine signaling is important for proper cellular behavior, differentiation, 
and proliferation, along with the concomitant extracellular matrix produced by the 
neighboring cells. Furthermore, optimization of process parameters (e.g. nozzle pressure, 
motion arm velocity, nozzle tip size etc.) and material parameters (e.g. biopolymer 
viscosity, crosslinking agent concentrations, etc.) have been done to achieve high-fidelity 
three-dimensional structures and seamless integration onto a microfluidic tissue micro-
organ chambers. 
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The first step in the biofabrication of the in vitro three-dimensional microfluidic 
microanalytical microorgan device is to establish the structural formability of liver cell-
embedded tissue constructs through the direct cell writing process. A micro-scale tissue 
analog has been designed and fabricated for studying drug metabolism or its 
pharmacokinetic effects on secondary organ function via direct deposition of a three 
dimensional heterogeneous cell-seeded hydrogel-based matrix. First, cells were 
encapsulated within alginate hydrogels and bioprinted through the system into a desired 
pattern within the microfluidic circuits. For alginate-cell suspension, we used an air-
actuated dispensing nozzle with a pre-specified internal diameter tip size.  A 0.2 μm filter 
was attached to the compressed air cylinder.  Prior to deposition, ethanol, filtered air, and 
deionized water were purged through the system. By integrating the bioprinting system 
with a CAD environment, notable feasibility and reproducibility of three-dimensional 
structures has been realized within micron-order dimensional specifications and hence 
can be used for parametric studies (Figure 3-5).  
   
Figure 3-5:  Bioprinted tissue construct structural formability 
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In this study, the process parameters (dispensing pressure of 2.0 psi with internal nozzle 
tip diameter of 200 μm) were adjusted to achieve a three-layered sinusoidal pattern with 
consistent strut diameters of 200 μm. 
3.2  Microfabrication of the Tissue Chamber 
The other major component of the three-dimensional microfluidic microanalytical 
micro-organ device is the micofluidic device with indented chambers that serve to house 
the bioprinted tissues. In order to form a closed platform for continuous drug perfusion 
flow studies, the micro-organ device consists of an assembly of two microfabricated 
components: 1) a polydimethylsiloxane (PDMS) substrate with indented chambers and 2) 
glass cover slide with etched microchannels that drain into and out of the tissue chamber.  
 
Figure 3-6: The micro-organ device represents an assembly of two microfabricated 
components 
The preferred material for fabrication of the substrate for housing the embedded tissue is 
PDMS, a biocompatible silicone rubber.  
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Figure 3-7: The chemical structure for polydimethylsiloxane (PDMS) 
The advantages of using PDMS for these microfabricated chambers include ease of 
bonding, optical properties, and permeability to gases for biological applications. The 
process for microfabricating a PDMS substrate with a 10mm x 10mm x 750uL tissue 
chamber is detailed in Figure 3-8.  
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Figure 3-8: Microfabrication of a PDMS stamp 
Essentially, photolithography is first applied to pattern a light-sensitive photoresist 
polymer (of approximate dimension 10 mm x 10 mm x 600 μm) onto a silicon wafer. 
Using soft lithographic techniques, PDMS is then cast onto the silicon wafer to yield a 
stamp (Whitesides et al., 2001). The PDMS stamp can then be used to accommodate the 
bioprinted micro-organ as well as a component in the microfluidic device. 
The cover glass layer consists of an etched bifurcating channel pattern and inlet 
and outlet holes drilled into the glass shown in Figure 3-9.   
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Figure 3-9: Etched microfluidic channel patterns on glass cover slide 
The dimensions of the channel pattern are 20.5 μm deep, with branching channel widths 
ranging from 817 μm down to 88 μm. The next step is to directly write the the cell-
encapsulated alginate constructs within the PDMS chamber. In order to integrate the 
alginate constructs onto the PDMS substrate, both the glass and PDMS layers are first 
cleaned with acetone and 70% ethanol and then placed into a RF plasma chamber 
(Harrick Plasma) to oxidize the glass and PDMS substrate surface methyl groups to form 
silanol groups. Therefore, a hydrophilic surface with good wettability and improved 
traction is attained.  
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Figure 3-10: Plasma treatment of PDMS substrate results in improved wettability 
Firstly, the chamber was put under vacuum for 1 min. Afterwards, the glass and PDMS 
surfaces were treated with air plasma for 30 sec. The PDMS layer was taken to the 
deposition system and the alginate-encapsulated HepG2 cell solution was deposited to 
create a sinusoidal flow pattern with 250 μm diameter struts (Figure 3-11) using the air-
actuated EFD dispensing nozzle.   
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Figure 3-11:  Prototype sinusoidal pattern in tissue chamber 
12.5 μm of 5.0% w/v calcium chloride and media were deposited using a pipettor to 
crosslink the alginate and feed the cells.  The PDMS was then bonded to the glass layer 
with the bifurcating channels aligned to the chamber.  The chips were allowed to 
strengthen their bonding for approximately 45 min – 1 hr. Through this process, the cell-
encapsulated alginate construct is directly bioprinted within the tissue chamber 
indentation on the PDMS microchip, thus forming an integrated three-dimensional tissue 
chamber unit.  
3.3  Assembly of the Micro-bioreactor 
The experimental apparatus setup of medium/drug flow circulation in the micro-
bioreactor for parallelization of study is shown in Figure 3-12 below.  
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Figure 3-12:  Parallelization of fully drug perfused tissue chambers 
 
To demonstrate effective drug metabolism in the liver chamber, a non-fluorescent 
prodrug is fed into the system through the inlet port, metabolized by the liver chamber, 
and then produced an effluent fluorescent metabolite for analysis collected at the outlet 
port. Results of such analysis will be used in the future to understand the relative 
pharmacokinetic efficiency as well as relevancy of the tissue chambers design for human 
application. The drug flow study protocol will include 120 μL of 10 mM EFC (7-ethoxy-
4-trifluoromethyl coumarin) stock solution mixed with 9.88 ml of HepG2 medium and 
put into a syringe to be infused by a syringe pump. The micro-organ prototype is then 
connected to the pump for simultaneous infusion at the inlet port and withdrawal at the 
outlet at a designated flow rate. The drug substrate is metabolized by the hepatocytes into 
the drug product or metabolite to be measured. The perfused micro-organs are 
subsequently incubated along with static, non-perfused controls. The effluent is collected 
within the withdrawal syringe and assayed with a cytofluoremeter for HFC drug 
metabolic conversion with a drug residence time consistent with the static controls.  
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3.4 Summary of Key Results and Conclusions 
The feasibility of using a standard soft-lithography technique is explored to fabricate 
microscale in vitro device with microchannels and multi-chambers to house the 
bioprinted tissue. PDMS elastomer soft lithography is combined with micromolding 
techniques to fabricate three-dimensional microfluidic tissue chambers.  
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CHAPTER 4.  MODELING FLUID DYNAMICS AND MASS TRANSFER IN THE 
LIVER MICRO-ORGAN 
 
This chapter examines the modeling of fluid dynamics and mass transfer effects of a 
continuously perfusing drug/media flow through a channel pattern defined by a 
bioprinted three-dimensional liver micro-organ that biomimicks the in vivo liver 
sinusoidal capillary architecture. In macroscale bioreactors, fluid flow and mixing are 
expected to affect tissue formation and function in at least two ways: by enhancing mass 
transfer (e.g., of gases, nutrients, and drugs) and by direct physical stimulation of the 
cells (e.g., by hydrodynamic forces). In this thesis, a microscale fluidic device is modeled 
wherein the micron-sized channel features enable relatively large hydrodynamic shear 
forces on the liver tissue constructs while preserving predictable laminar flow regimes. In 
order to comprehensively evaluate the impact of fluid flow on cell-specific function, in 
particular liver-specific drug metabolic function, an accurate determination of the fluid 
flow parameters (e.g. shear stress and mass transfer) experienced by the bioprinted liver 
tissue is important in determining several design parameters such flow rate and 
microchannel dimensions to ensure that the liver cells encapsulated in the bioprinted 
tissue construct are subjected to the same type of fluidic microenvironment as they would 
inside the liver sinusoid capillaries. Below is a schematic of the configuration for the 
micro-organ being modeled in Figure 4-1. 
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Figure 4-1: Modeling configuration for liver micro-organ 
In this thesis, COMSOL Multiphysics software is implement to model fluid dynamical 
properties and mass transport phenomena for microfluidic flow through the liver micro-
organ. COMSOL Multiphysics is a finite element analysis and solver software package 
for various physics and engineering applications, especially coupled phenomena, or 
multiphysics. The overall modeling strategy is shown in Figure 4-2. 
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Figure 4-2: Overall modeling strategy of fluid dynamics and mass transfer in COMSOL 
4.1 Computational Fluid Dynamic Model for Shear Stress Distributions  
Shear stress is an inherent part of microfluidic perfusion culture systems and is often 
perceived as a limiting factor in microfluidic perfusion culture due to its deleterious 
effect on cells at high levels. However, it is possible to design and operate microfluidic 
perfusion culture systems such that applied shear stresses are orders of magnitude below 
those at which adverse effects are observed. Methods for mitigating shear stress include 
lower fluid velocities, designing high aspect ratio cell culture chambers, and including 
micropillars or microwells to shield cell cultures. On the other hand, some microfluidic 
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perfusion systems use high levels of shear stress to investigate biological phenomena, 
such as endothelial cell function or cell adhesion. In addition, acceptable levels of shear 
stress can vary widely depending on cell type.  
Physiological values of shear stress on endothelium lining of vessels in vivo are in 
the range of 1-15+ dyne/cm2 (Davies, 1995, Malek et al., 1999). The shear stresses on 
cells at the chamber/tissue inferface are well below this range, whereas the shear stresses 
at the fluid/tissue interface for perfusion flow in the channels approach the lower limit. 
Physiological values of fluid shear stress on tissue cells other than endothelium are 
infrequently reported or cited in the current literature. However, analysis of interstitial 
flow through the internal elastic lamina of blood vessels suggests that smooth muscle 
cells bordering the subendothelial intima experience wall shear stresses on the order of 1 
dyne/cm2 (Tada et al., 2000), a value that affects smooth muscle cell biology in vitro 
(Papadaki et al., 1998). Furthermore, as detailed in Chapter 2, the endothelial cells lining 
the liver perfusing capillary vasculature closely approximate the drug metabolizing 
hepatocytes. Therefore, one may deduce from the anatomy of the microvasculature that 
the highly fenestrated or porous liver endothelium depicted in Figure 4-3 results in 
notable transmission of fluid shear stresses to hepatocytes with significant biological 
consequences that may modulate drug metabolism activity. 
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Figure 4-3: The highly fenestrated sinusoidal liver microcirculation may lead to high 
fluid shear stress transmission to liver cells 
In the development of a physiologically relevant microenvironment for hepatocyes in the 
liver, it is essential to adequately recapitulate the perfusion of the hepatocellular 
parenchyma by the sinusoidal capillary network. Although the effects of fluid shear stress 
on hepatocytes have been less well-documented than effects on blood vessel-lining 
endothelial cells, shear stress has been reported to induce P4501A1 activity in hepatoma 
cells in microcarrier culture (Mufti and Bleckwinn, 1995, Mufti and Shuler, 1995) and to 
simulate metabolic function and morphogenesis in two dimensional co-culture of primary 
rate hepatocytes with nonparenchymal cells when shear stress levels were maintained at 
4.7 dyne/cm2 compared to no shear (Kan et al., 1998). The albumin production activity of 
liver tissue can also be enhanced by loading an adequate shear stress (Ijima et al., 2008); 
thus, the mild shear stress conditions in our system are likely to be good for the 
expression of liver-specific functions. Furthermore, it is expected that improvements in 
the mass transfer around the cells will greatly improve the clearance of drugs with an 
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extremely high extraction ratio, such as lidocaine. For these reasons, the expression of the 
liver-specific functions of hepatocytes would be expected to be higher in a circulation 
culture than in a stationary culture. 
  The optimal flow conditions of a microbioreactor should not be determined 
through a trial-and-error approach, but rather should be supported by precise simulation 
methods. Computational fluid dynamic (CFD) software packages (e.g. COMSOL) have 
been increasingly developed during the past decade and are a powerful tool to calculate 
flow fields, shear stresses and mass transport within and around three-dimensional 
constructs. Fluid flow inside the microbioreactor may be analyzed using a computational 
fluid dynamic (CFD) model to estimate the velocity profiles, pressures, and fluid shear 
stresses present within the system. The microbioreactor flow pattern geometry, when 
sufficiently complicated as in the case of a liver sinusoidal capillary, requires a full 
computational model to supplement simple analytical calculations. Computational fluid 
dynamic models have been used to calculate the momentum and oxygen transport within 
a concentric cylinder bioreactor for cartilage tissue engineering and to design and 
characterize a scaled-up version. A CFD model of direct perfusion through a three-
dimensional mesh demonstrated that the random fiber architecture of the scaffold would 
yield highly variable shear stresses; a scaffold with a homogeneous distribution of pores 
would therefore enable more precise control over the shear stresses. In this regard, it is 
becoming increasingly clear that design requirements for scaffolds used in tissue 
engineering should not be limited to considerations on biocompatibility and mechanical 
properties, but should also include a critical evaluation of pore structure and 
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interconnectivity, which must be tuned to the specific flow conditions used. Based on the 
range of flow rates seen in in vivo hepatic sinusoids (Davies et al., 1993, Davies, 1997, 
Kan et al., 1998), Powers et al sets the perfusion crossflow rate for a microfabricated 
perfusion bioreactor between 40 μl/min and 600 μl/min in order to mimic shear rates seen 
in the in vivo microenvironment (Powers et al., 2008). Levesque et al. uses a parallel-
plate flow chamber in to study the response of bovine endothelial cells in response to 
fluid shear stress (Leveque et al., 1985). These results showed that endothelial cells orient 
with the flow direction and become more elongated when exposed to higher shear stress. 
Effects of microchannel sizes on this angular orientation of the endothelial cells was 
demonstrated by Bonnie et al. who uses microchannels with channel width decreasing 
from 225 μm to 25 μm (Bonnie et al., 2002). This demonstrated how endothelial cells 
cultured in narrower microchannels are oriented primarily along the channel lengths, 
while cells grown in wider channels progressively lost this preferred orientation and 
ultimately randomly oriented within the largest microchannels. This result was an 
example of how geometric control of cell shape and orientation can be accomplished by 
culturing cells in microchannels of different widths. Another example of dimensional 
considerations for microchannel flows was considered by Ledezma et al. in which the 
dimensional ranges were investigated for a constant perfusion rate, the chamber height 
strongly affected the mechanical shear stress on the cells in that significantly reduced 
chamber heights resulted in physiologically unrealistic shear stress values (Ledezma et 
al., 1999). 
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In this thesis, the fluid dynamics within the three-dimensional microfluidic 
microanalytical micro-organ can be modeled using the complete form of the Navier-
Stokes equations in three dimensions, without any initial relaxations or approximations. 
The basic governing equations for viscous incompressible fluid flow are: 
Continuity:    0, =iiv             (1) 
Momentum:   jijjij
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where ρ  is the mass density of the fluid, iv is a component of the fluid velocity and ijτ is 
the ijth component of the stress tensor and where 
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p is the fluid pressure and μ  is the coefficient of viscosity. 
Therefore, the primary outputs from the computational fluid dynamical analysis 
are the fluid velocity profile and the wall shear stress. For microfluidic perfusion culture 
simplified as a two dimensional Poiseuille flow system, the resulting parabolic flow 
profile yields a simple estimate of shear stress at the wall: 
wh
μQ
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6=  where µ = viscosity [
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Q = flow rate [
s
m3 ], 
h = channel height [m], and 
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w = channel width [m]. 
In COMSOL, this wall shear stress is modeled using Navier-Stokes equation for 
incompressible fluid in the laminar flow regime. Based on the tissue chamber dimension 
of 10 mm x 10 mm x 600 μm, and a minimum 4 hr drug/media incubation period 
required for appreciable drug conversion in static cultures of bioprinted tissue constructs, 
the volumetric flow rate is set as 0.015 ml/hr for the drug flow perfusion studies. For all 
simulations performed in COMSOL, tetrahedral elements were used to set the mesh 
distribution in the geometry shown in Figure 4-4.  
 
Figure 4-4: Tetrahedral mesh element distribution in COMSOL 
The conditions for this simulation include an inlet volumetric flow rate of 1.5 x 10-2 
ml/hr, 3.0% w/v bioprinted alginate concentration, 1 x 106 total HepG2 liver cells 
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encapsulated. Different channel widths of 150 μm, 250 μm, and 400 μm are simulated to 
predict effect of varying channel dimensions on drug wall shear stress in Figure 4-5.  
     
Maximum Shear Shear as Function of Channal Width
0.0277
0.0160
0.0100
0.0000
0.0050
0.0100
0.0150
0.0200
0.0250
0.0300
150 um 250 um 400 um
Microchannel Width
Fl
ow
 S
he
ar
 S
tr
es
s 
[d
yn
m
/c
m
^2
]
 
Figure 4-5: Effect of varying channel width dimension on wall shear stress 
 
These results show that decreasing the channel width results in an elevated maximum 
wall shear stress. A simulation on varying velocities for a given channel width gave 
expected results with proportionately higher wall shear stresses for higher initial 
volumetric flow rates. 
4.2 Mass Transfer Model in COMSOL 
The microbioreactor offers the benefit of improved mass transfer that is provided 
by perfusion, stirring, or rotation. The physical system that is being modeled in 
COMSOL is that of a hollow fiber through which drug reactant solute in nutrient media 
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flows with a fully developed laminar parabolic velocity profile. The wall of the tube 
constitutes a membrane phase made up of cells encapsulated in alginate. Media and drug 
transport in the hollow fibers occurs through a non-trivial interaction of convection and 
diffusion, modulated by a number of factors. The drug reactant is transported by 
convection and diffusion in the liquid media phase, whereas diffusion is the only 
transport mechanism in the membrane phase. To describe the system, the following mass 
transport equations can be formulated: 
0)( 11 =+∇−⋅∇ uccD  in liquid phase                    (6) 
0)( 2 =∇−⋅∇ cDm   in membrane phase        (7) 
where ci denotes the concentration of the drug reactant (mol/m3) in the respective phases, 
D denotes the diffusion coefficient (m2/s) in the liquid phase and Dm is the diffusion 
coefficient in the membrane, while u denotes the velocity (m/s) in the liquid phase. 
 The convection-diffusion equation is applied to both domains and coupled to the 
fluid velocities of the momentum transport equations. An idealized tissue-channel 
geometry containing cylindrical conduits for convective flow forms the basis for the 
numerical analysis with a mass transfer model. Species diffusion and enzymatic reaction 
are assumed as the only contributing factors to mass conservation within the tissue. The 
basis species conservation equations can be used to solve for the coupled tissue-conduit 
species concentration profile. These equations in their most generalized form are 
(assuming constant density and diffusivity): 
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and Di is the diffusivity of the ith species, Ci is the concentration of the ith species in the 
tissue, Rvi is the cellular uptake or release rate of the ith species, and r, θ , and z represent 
the cylindrical coordinates used to describe the system. Since the tissue can be assumed 
solid and non-porous, the species conservation equation at steady state applicable to the 
tissue reduces to: 
                                                               0,
2 =+∇ vitissueii RCD                                        (10) 
where Ci,tissue represents the ith metabolite concentration in the tissue.  
The cell uptake or release rate of the drug metabolite is assumed to follow Michaelis-
Menten kinetics: 
                                                                   
m
vi KC
CV
R +=
max                                               (11) 
where Vmax and Km are the appropriate Michaelis-Menten parameters respresenting the 
maximal enzyme activity and the substrate concentration at which the activity is half the 
maximal, respectively. 
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The appropriate boundary conditions needed to solve for the concentration profile 
in the tissue include the insulation boundary condition at the walls of the chip, flux-
continuity at the tissue-fluid interface, and appropriate concentrations at the top and 
bottom plane surfaces of the tissue construct.  
                                                                0, =∇− walltissueiCD                                          (12) 
 The species conservation equation in the channel with the Poiseuille flow 
approximation (which follows from the fluid dynamic modeling described in the previous 
section) reduces at steady state to: 
                                                         fluidi
fluidi
z CDz
C
v ,
2, ∇=∂
∂−                                       (13) 
The appropriate boundary conditions needed to simulate the metabolite distribution in the 
channel include the continuity of fluxes at the fluid-tissue interface and a valid inlet 
concentration of the substrate Co. 
         tissuefluidfluidifluidtissuetissuei CDCD −− ∇−=∇− ,,                       (14)                        
 Prior to modeling mass transfer in COMSOL, the constants Vmax and Km first 
need to be determined through experimentation. Assuming Michaelis-Menten kinetics, it 
is important to determine the maximum rate of an enzyme mediated reaction through a 
series of experiments carried out with varying substrate concentration ([S]) and the initial 
rate of product formation is measured. Initial here is taken to mean that the reaction rate 
is measured after a relatively short time period, during which complex builds up but the 
 84 
 
substrate concentration remains approximately constant and the quasi-steady-state 
assumption will hold. For Michaelis-Menten kinetics, the enzymatic reaction is assumed 
to be irreversible, and the product does not bind to the enzyme: 
                                                                                   (15) 
The first key assumption in this derivation is the quasi-steady state assumption (or 
pseudo-steady-state hypothesis), namely that the concentration of the substrate-bound 
enzyme ([ES]) changes much more slowly than those of the product ([P]) and substrate 
([S]). The second key assumption is that the total enzyme concentration does not change 
over time, thus we can write the total concentration of enzyme as the sum of the free 
enzyme in solution and that which is bound to the substrate.  
  Using the drug substrate EFC (7-ethoxy-4-trifluoromethylcoumarin) for our 
model, varying substrate concentrations are reacted with bioprinted hepatocyte-
encapsulated samples of a given cell density in static culture (see Chapter 6). The specific 
enzyme being probed for this kinetic reaction is 7-Ethoxycoumarin O-deethylase selected 
for in the cytochrome P450 CYP2B6. A saturation curve for an enzyme showing the 
relation between the concentration of substrate and rate allows for the determination of 
Km and Vmax. In literature, reported values for CYP2B6 catalyzed EFC O-deethylation as 
the test reaction include an EFC Km value of 4.0 μM (1.6–6.4 μM, 95% confidence 
interval) and a Vmax value of 2.4 nmol/(min x nmol CYP) (1.8–3.0 nmol/(min x nmol 
CYP)) (Korhonen et al., 2007). Another set of kinetic characteristics have been tabulated 
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using the EFC fluorescent probe assays in intact CYP2B6-expressing cells and found Km 
and Vmax values of 4.2±2.8 μM and 35.1±4.9 pmol/min·mg, respectively. (Donato et al., 
2004). In this thesis, Km and Vmax are determined by evaluating the rate of EFC 
metabolism in cultured cells over a substrate concentration range of 0.3 to 100 μM. From 
this analysis, the Km and Vmax values for a bioprinted HepG2 encapsulated tissue 
constructs of initial cell number of 1 x 106 cells are 3.8 μM and 0.3 nmol/s·cell, 
respectively. Based on size of EFC (MW=258.2 g/mol), the diffusion coefficient Dm and 
partition coefficient for EFC through 3.0% w/v  alginate concentration are set at 5.0 x 10-
5 cm2/s and 0.98, respectively, as interpolated for literature values.  
 In order to establish a predictive model of drug metabolism in bioprinted liver 
tissue constructs, the flow rate must be sufficiently high enough to recapitulate 
nutrient/waste exchange as in the in vivo vasculature, but at the same time provide 
sufficient drug/media residence time in the perfused tissue chamber to ensure a 
measurable drug metabolic response. Based on the tissue chamber dimension of 10 mm x 
10 mm x 600 μm, and a minimum 4-hr drug/media incubation period required for 
appreciable drug conversion in static cultures of bioprinted tissue constructs, the 
volumetric flow rate is set as 0.015 ml/hr for the drug flow perfusion studies. 
 The effluent concentration of drug metabolite (i.e. HFC) can be predicted by 
simulating the sinusoidal drug flow pattern in COMSOL’s convection-diffusion module. 
The conditions for this simulation include an inlet volumetric flow rate of 1.5 x 10-2 
ml/hr, 3.0% w/v bioprinted alginate concentration, 106 total HepG2 liver cells 
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encapsulated. Different channel widths of 150 μm, 250 μm, and 400 μm are simulated to 
predict effect of varying channel dimensions on drug conversion in Figure 4-6. 
  
 [HFC]max = 0.769 μM         [HFC] max = 0.770 μM               [HFC] max = 0.770 μM  
 [HFC]min = 0.705 μM         [HFC] min = 0.755 μM            [HFC] min = 0.765 μM 
(a) 150 um channel width        (b) 250 um channel width      (c) 400 um channel width  
Figure 4-6: Effect of varying channel width dimension on drug metabolite concentration 
Tissue construct strut widths of 250 μm and overall construct volume is maintained as a 
constant for all samples to maintain cell numbers across all dimensional variations. While 
the differences in drug metabolic conversion are small for the different channel widths, 
the minimum HFC concentration at steady-state is observed to increase as the channel 
width increases since the linear transit time of the drug increases for larger channel 
widths, thereby exposing the substrate EFC to enzymatic conversion by the cells for a 
longer duration.   
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 For a channel width of 250 μm, initial volumetric flow rates of 1.5 x 10-4 ml/hr,  
1.5 x 10-2 ml/hr, and 1.5 ml/hr are simulated to predict effect of varying initial volumetric 
flow rates on drug conversion in Figure 4-7.  
 
 [HFC]max = 0.770 μM               [HFC] max = 0.770 μM          [HFC] max = 0.769 μM                         
 [HFC]min = 0.770 μM               [HFC] min = 0.755 μM [HFC] min = 0.206 μM 
(b) Q = 1.5 x 10-4 ml/hr            (b) Q = 1.5 x 10-2 ml/hr (c) Q = 1.5 ml/hr  
Figure 4-7: Effect of varying volumetric inlet flow rate on drug metabolite concentration 
For a given channel width, the HFC concentration at steady-state is observed to decrease 
as the initial volumetric flow rate increases since the overall transit time of the drug 
decreases at higher volumetric flow rates, thereby exposing the substrate EFC to 
enzymatic conversion by the cells for a shorter duration.   
4.3 Summary of Key Results and Conclusions 
Fluid shear has been shown to activate cell signaling pathways and influence 
differentiated function of both hepatocytes and endothelial cells. An accurate 
determination of the shear stress experienced by the biomanufactured tissue is therefore 
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important in determining several design parameters such as flow rate and geometry to 
ensure that the cells in the bioreactor are subjected to the same kind of environment as 
they would inside the liver capillaries. The shear stresses at the fluid/tissue interface for 
perfusion flow in the channels approach the lower limit of physiological values for shear 
stress on endothelium lining of vessels in vivo. The microbioreactor flow pattern 
geometry, when sufficiently complicated as in the case of a liver sinusoidal capillary, 
requires a full computational model to supplement simple analytical calculations. This 
section reviews in detail approaches to the fluid dynamical and transport modeling of 
flow in microscale bioreactors in which biological tissue is maintained in channels by 
continuous perfusion of culture medium. In addition, to better understand the tissue 
disposition of a candidate drug, a comprehensive mass transfer model is also considered 
and developed. For fluid dynamical predictions, wall shear stress is calculated by solving 
Navier-Stokes equations for incompressive fluid flow in a laminar flow regime in 
COMSOL to predict the effect of microchannel dimensions and flow rate on wall shear 
stress. The simulations showed that for a given initial volumetric flow rate, decreasing 
the channel width results in an elevated maximum wall shear stress. A simulation on 
varying velocities for a given channel width gave expected results with proportionately 
higher wall shear stresses for higher initial volumetric flow rates. In the study of mass 
transfer effects, the effluent concentration of drug metabolite (i.e. HFC) can be predicted 
by simulating the sinusoidal drug flow pattern in COMSOL’s convection-diffusion 
module. By varying the microchannel dimensions, it was observed from the simulation 
that the minimum HFC concentration at steady-state is observed to increase as the 
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channel width increases since the linear transit time of the drug increases for larger 
channel widths, thereby exposing the substrate EFC to enzymatic conversion by the cells 
for a longer duration. Finally, for a given channel width, the HFC concentration at 
steady-state is observed to decrease as the initial volumetric flow rate increases since the 
overall transit time of the drug decreases at higher volumetric flow rates, thereby 
exposing the substrate EFC to enzymatic conversion by the cells for a shorter duration.   
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CHAPTER 5.  CELL VIABILITY CHARACTERIZATION ON EFFECT OF KEY 
BIOFABRICATION PROCESS PARAMETERS 
 
Novel technologies such as the direct cell writing process are emerging that 
incorporate cells as part of the building blocks for various layered biomanufacturing 
processes for the freeform fabrication of tissue constructs in tissue regeneration, 3D 
pharmacokinetic models, cell-based MEMS, sensors, and microfluidic devices. Now, we 
are attempting to use cells as building blocks to manufacture biological structures. 
However, the effects of these biomanufacturing processes on cells have not been fully 
studied.  
Cells, bioactive substances, and scaffold materials are the three major elements of 
tissue engineering. It is often overlooked that cells may not remain viable and/or of the 
desired phenotype after undergoing the mechanical forces used to process bioactive 
substances and scaffolding materials during the biofabrication. Furthermore, mechanical 
models of cell manipulation are often based on assumptions of a standard viscous or 
viscoelastic continuum or an elastic nucleus within a viscous cytoplasm (Evans et al., 
1989, Schmid-Schoenbein et al., 1995, Dong et al., 1991). Biological studies show that 
living cells are dynamic structures that change their growth, locomotion, and 
differentiation under external mechanical influences (Wang et al., 2001). Alteration in 
mechanical signals caused by changes of cell geometry may result in chemical signals 
that modulate downstream cellular development (Clark et al., 1995, Plopper et al., 1995). 
During the biofabrication process, cells are invariably subjected to mechanical forces. 
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These process-induced mechanical forces may affect the intracellular structures of the 
cell (Ingber, 1993, Ingber, 1997). For many biological applications, it is important to 
know whether cells remain viable and/or the desired phenotype after undergoing the 
mechanical forces applied during the process. Taking a syringe-based cell dispensing as 
an example, different process parameters will produce different effects on cells: 
decreasing in the dispensing nozzle size will increase the dispensing shear forces 
experienced by cells inside the nozzle; varying the nozzle head movement speed could 
also induce additional compressive or tensile forces on the deposited strands with respect 
to the substrate, for example, at a high speed, the deposited strand may be “stretched” and 
cause an additional tensile force to the embedded cells, while at a low speed, the forces 
may be lower, or even compressive in nature.  Therefore, it is important that any process-
induced effects on cells during the biofabrication are better understood.  
This chapter specifically examines the effect of the solid freeform fabrication 
based direct cell writing process, focusing on dispensing pressure and nozzle size, on the 
viability of liver cells within alginate. Cell viability assays are conducted to evaluate the 
effect of varying cell/material dispensing process parameters on cell survival. Sodium 
alginate is chosen as the biopolymer material to be utilized during the testing of the cell 
dispensing process. 
5.1 Effect of Dispensing Pressure and Nozzle Size on Cell Viability 
In this set of studies, hepatocytes are bioprinted and encapsulated within a three-
dimensional alginate tissue construct. To prepare the polymer solution, medium viscosity 
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sodium alginate powder (Sigma, St. Louis, MO) is dissolved in deionized water as a 3.0% 
(w/v) solution. The ionic crosslinking solution is prepared by dissolving 5.0% (w/v) 
calcium chloride (Sigma, St. Louis, MO) in deionized water. The cells selected are 
HepG2 liver cells (ATCC, MA) which are cultured and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, ATCC), supplemented with 10% (w/v) fetal bovine 
serum and maintained in the incubator at 5% CO2 and 37°C. The cells were gently mixed 
in viscous sodium alginate solution with Pasteur pipet to ensure a uniform cell 
distribution. Hemocytometer readings measured the cell concentration at 1x106 cells/mL 
of alginate biopolymer solution. HepG2 cells are chosen because of its usefulness in 
pharmacokinetic studies and potential for in vitro tissue-on-chip applications. 
For the cell viability study, each bioprinted sample are submitted to the Live/Dead 
Assay (Molecular Probes, Inc). The samples are viewed in a Leica fluorescence 
microscope under 40X magnification. In order to quantify the cell viability and assign a 
cell viability percentage throughout the time course study, each bulk sample is visualized 
and a live-dead cell count is performed at five different locations. The 5 different 
locations for the bulk sample are chosen using a protocol whereby the locations were 3 
peripherally and 2 centrally. All 5 sample locations for the bulk samples are observed to 
reside on the surface due to focal constraints.   
Two studies are performed, one short-term and another at longer time points. The 
aim of the short-term study is to evaluate the cell viability ratios at three incremental time 
points: 0 hr, 12 hr, 24 hr. The aim of the longer time point study is to evaluate the cell 
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viability ratios at three incremental time points: 0 day, 3 day and 7 day. The experimental 
setup for each parametric study involves twelve experimental groups and one control 
group. Two basic cell dispensing process parameters are studied: the nozzle tip internal 
diameters at 150 um, 250 um, 400um and the dispensing pressures at 5 psi, 10 psi, 20 psi, 
and 40 psi.  Each experimental group comprises a sample size of four (i.e. n = 4). The 
control group consists of collecting alginate-cell solution directly from the reservoir 
under the passive effect of gravity. All experimental samples are dispensed as bulk 
material and weighed with a mass balance to a previously determined uniform mass. 
Upon completion of deposition, each sample is immediately submerged into a 5.0% (w/v) 
CaCl2 crosslinking solution for a five-minute duration before perfusion with media and 
incubation. All samples in the long-term study are cross-linked daily to maintain both cell 
immobilization and structural integrity. 
A first set of parametric experimental studies are conducted to assess the effect of 
the dispensing pressure and the nozzle size on the viability of cells. Each data point is an 
average of five representative Live/Dead images for each sample. Analysis is first 
performed by segregating the samples into three experimental groups according to 
different nozzle diameters of 150 μm, 250 μm, and 400 μm.  Results of the parameter 
study are presented in Figure 5-1a for cell viability as function of dispensing pressure and 
Figure 5-1b as a function of nozzle diameter, respectively.  
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Figure 5-1: Effect of process parameter on cell viability for 24-hr study 
 
It can be observed from the figures that cell viability varies with dispensing pressure and 
nozzle diameter. Cell viability increases as dispensing pressure decreases and/or nozzle 
diameter increases. 
The first general observation from the cell proliferation assay is that the control 
group demonstrated no change in cell proliferation during the 24-hr period as well as the 
7-day period due to the cell-immobilizing alginate gel matrix which is daily replenished 
with crosslinking ions. The consequence is that no cell proliferation occurs throughout 
the studied periods and any increase in cell viability in the experimental groups may be 
attributed to cell recovery from mechanical cell damage. For the experimental group 
varying nozzle diameters, there is a statistical drop in cell viability between the control 
group and the bioprinted cell encapsulated tissue constructs immediately after dispensing 
(0 hr) and at the 6 hr time point.  Cell viabilities of the experimental samples at the 0 hr 
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time point for the nozzle diameters studied (150, 250, and 400 μm) are 68.60%, 76.15%, 
and 76.41% respectively of the control values.  
For the experimental group varying dispensing pressures, there also exists a 
significant difference in cell viability over the time course, especially at the initial time 
point.  Observed is a statistically significant drop in cell viability between the control 
group and the bioprinted cell encapsulated tissue constructs immediately after dispensing 
(0 hr) and at the 6 hr time point. The cell viabilities of the experimental samples at time 0 
hr for the dispensing pressures studied (i.e., 5, 10, 20, and 40 psi) are 84.30%, 82.71%, 
68.99%, and 58.89% respectively of the control values.  
5.2 Effect of Dispensing Pressure and Nozzle Size on Cell Recovery 
Cell recovery is also observed as a function of the process parameters and 
quantitative date is calculated for the percentage of cell recovery at the different culture 
times. Figure 5-2 shows a trend of cell recovery as a function of dispensing pressure 
(Figure 5-2a) and nozzle tip diameter (Figure 5-2b) referenced to the control group 
sample measured at 0 and 24 hr culture time points. The results of cell recovery data is 
presented in the following way: to study the cell recovery as a function of dispensing 
pressure as shown in Figure 5-2a, for a given pressure, the cell recovery experimental 
data is first measured for every nozzle diameter, and then averaged together and plotted 
in the figure; to study the cell recovery as a function of nozzle diameter as shown in 
Figure 5-2b, for a given nozzle diameter, the cell recovery experimental data is first 
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measured for every dispensing pressure, then averaged over all the data together and 
plotted in the figure.  
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Figure 5-2: Cell recovery as referenced to control group for 24-hr study. (a) cell 
recovery as function of dispensing  pressure; (b) cell recovery as function of nozzle 
diameter 
 
All experimental groups for dispensing pressure (i.e., 5, 10, 20, and 40 psi) show 
significant cell recovery at the 24 hr time endpoint with cell viabilities at 98.34%, 
92.69%, 89.98%, and 88.94% respectively of the control values. The smallest nozzle 
diameter group (i.e., 150 µm) demonstrates significantly diminished cell recovery with 
percentage cell viability of the control at 24 hr of 80.82%. The larger nozzle tip diameter 
experimental groups (250 and 400 µm) show comparatively higher cell recovery at the 
study’s endpoint with cell viability at 94.91% and 100% respectively of the control 
values. The results of cell recovery at a longer time point are shown in Figure 5-3 as a 
function of the dispensing pressure (Figure 5-3a) and as a function of nozzle tip diameter 
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(Figure 5-3b), referenced to the control group sample measured at 0 and 7day culture 
time points.  
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Figure 5-3: Cell recovery as referenced to control group for 7-day study. (a) cell 
recovery as function of dispensing  pressure; (b) cell recovery as function of nozzle 
diameter 
 
All experimental groups for dispensing pressure (i.e., 5, 10, 20, and 40 psi) show 
significant cell recovery at the 7-day study endpoint with cell viability at 94.67, 91.07%, 
90.02%, and 87.06% of control values. The smallest nozzle diameter group (i.e., 150 µm) 
shows significantly diminished cell recovery with percentage cell viability of the control 
at 7 days of 84.70%. The larger nozzle diameter experimental groups (250 and 400 µm) 
again shows comparatively higher cell recovery at the study’s endpoint with cell viability 
at 94.13% and 97.33% of the control values. 
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Figure 5-4 shows the percentage of cell recovery by comparison of the cell 
viabilities at two culture time windows: 0 hr to 6 hr and 0 hr to 24 hr as a function of 
pressure (Figure 5-4a) and nozzle tip diameter (Figure 5-4b).  
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Figure 5-4: Percentage of cell recovery for 24-hr study. (a) percentage of cell recovery 
function of  dispensing pressure; (b) percentage of cell recovery as function of nozzle 
diameter 
 
From the cell recovery data presented in Figure 5-4, different cell recovery sensitivities 
are observed for the process parameters: cell recovery is higher for high pressure (i.e., 
percentage recovery: 53.39% at 40 psi averaged over all nozzle tip diameters), see Figure 
5-4a, and cell recovery is less for small nozzle tip diameter (i.e, percentage recovery: 
23.07% at 150 um average over all pressures), see Figure 5-4b. The observed values for 
percentage recovery over the first 6 hours of study for the three nozzle tips (i.e., 150, 250, 
400 µm) are 3.64%, -0.54%, and 1.81% respectively. The percentage recovery over the 
24-hr period for the three nozzle diameters (i.e., 150, 250, and 400 µm) is 23.07%, 
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28.31%, and 37.04% respectively. The percentage recovery over the first 6 hours of study 
for the dispensing pressures (i.e., 5, 10, 20, and 40 psi) is -2.23%, 0.20%, 4.59%, and 
4.03% respectively.  The percentage recovery over the 24-hr period for the dispensing 
pressure (i.e., 5, 10, 20, and 40 psi) is 18.44%, 13.84%, 32.23%, and 53.39% 
respectively. 
Figure 5-5 shows the percentage of cell recovery by comparison of the cell 
viabilities at two culture time windows corresponding to the longer study period: 0 day to 
3 day and 0 day to 7 day as a function of pressure (Figure 5-5a) and nozzle tip diameter 
(Figure 5-5b).  
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Figure 5-5: Percentage of cell recovery for 7-day study. (a) percentage of cell recovery 
function of dispensing pressure; (b) percentage of cell recovery as function of nozzle 
diameter 
 
Comparing the cell recovery data from these two culture windows presented in Figure 5-
5, no new significant cell recovery occurs after a certain time point for both process 
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parameters studied. The observed values for percentage recovery over the first 3 days of 
study for the three nozzle tips (i.e., 150, 250, 400 µm) are 19.29%, 25.09%, and 26.07% 
respectively. The percentage recovery over the entire 7-day period for the three nozzle 
parameters (i.e., 150, 250, 400 µm) is 19.26%, 24.90%, and 26.56%, respectively. The 
percentage recovery over the first 3 days of study for the dispensing pressures (i.e., 5, 10, 
20, 40 psi) is 18.25%, 16.74%, 24.47%, and 34.45% respectively.  The percentage 
recovery over the 7-day period for the dispensing pressures (i.e., 5, 10, 20, 40 psi) is 
18.35%, 17.46%, 25.04%, and 36.64% respectively.  
5.3 Summary of Key Results and Conclusions 
In the solid freeform fabrication based direct cell writing process, the application 
of external loads to cells is likely to occur at different spatial, temporal, and material 
levels during dispensing. Taking the reported cell dispensing system as an example, the 
mechanical disturbance may be contributed by the dispensing pressure, deposition speed, 
the dispensing nozzle size and length, and the hydrogel rheological properties. The 
preliminary cell viability and recovery data suggest that during and after dispensing, cells 
may have three distinct responses: (1) survival with desired phenotype (i.e., capable of 
proliferation), (2) survival but quiescent, or (3) necrosis. As time passes, cells in a 
quiescent state may also demonstrate three further behaviors: (1) sustain mechanical 
stress but able to recover original capabilities, (2) phenotypic change and/or de-
differentiation, or (3) have undergone damage leading to apoptosis.  
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During the 24-hr study, increases in quantitative cell viability (cell recovery) over 
time may have been attributed to initial process-induced mechanical cellular attrition, 
which is reversible with time for quiescent cells. This is a safe assumption as the control 
group demonstrates no change in cell viability during 24-hr period due to a cell-
immobilizing alginate gel matrix. Therefore, no cell proliferation is observed throughout 
the study period and we considered that the increases in cell viability after time may be 
attributed to cell recovery from the mechanical pertubation. Comparing the two 
dispensing parameters studied (i.e., dispensing pressure and nozzle diameter) during the 
24-hr cell viability study, the average cell viability and/or cell recovery appears more 
likely to increase due to reduced dispensing pressure than increased nozzle diameter. 
Furthermore, different cell recovery results at the extreme conditions are observed (i.e. 
53.39% at 40 psi versus 23.07% at 150 um). Differences in the initial viability and 
eventual recovery may indicate differences in the severity and type of mechanical on the 
dispensed cells. Furthermore, the cell recovery for the longer time point 7-day study 
shows no significant cell recovery between the initial culture window to the study 
endpoint, which indicates that the majority of cell recovery occurred over the first 24 
hours. 
When a functioning live cell is impinged upon by the dispensing process, the 
array of mechanical forces sustained by the cell may result in a number of distinctive 
outcomes. Specifically, mechanically-induced damage to cell viability, as shown during 
short-term studies (i.e., 24 hr), appears likely to affect construct viability more than all 
other scaffold rendering parameters. The results of this study suggest that the effect of 
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dispensing parameters on cell viability initially may be reversible with time, and the 
severity of the effects of the two parameters studied here, cell dispensing pressure and 
nozzle diameter, on cell viability and/or eventual recovery response was not equally 
contributory. Also, taking both the 24-hr and 7-day cell recovery studies herein into 
account, a significant cell recovery from mechanical process-induced damage appears to 
take place over the first 24 hours with no significant cell recovery thereafter. This may 
provides a necessary temporal benchmark for functional study and perfusion flow studies 
of dispensed hepatocytes through the direct cell writing process.  
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CHAPTER 6.  BIOLOGICAL CHARACTERIZATION OF BIOPRINTED 
THREE-DIMENSIONAL MICRO-ORGAN 
 
6.1 The Rational for Bioprinting Three-dimensional Tissue Constructs 
6.1.1  Three-dimensional Scaffolds for Enhanced Osteoblastic Function 
Although microfluidics has naturally catalyzed the development of miniaturized 
two-dimensional culture for in vitro use, development of three-dimensional microscale 
bioreactors is a relatively novel approach in tissue engineering (Khetani et al., 2006, 
Eschbach et al., 2005, Kane et al., 2006). The ability to bioprint three-dimensional 
structures into a microfluidic system is extremely important because of studies indicating 
that three-dimensional culture can produce significant differences in cell functional 
behavior (Abbot 2003, Weaver et al., 1997, Wolf et al., 2003, Sahai et al., 2003).  
A comparison study of biological cell proliferation and function of osteoblasts 
cultured using two types of 3D Insert™ versus two-dimensional conventional monolayer 
is conducted. The 3D Insert™ are polymeric three-dimensional porous constructs 
designed for use with multi-well polystyrene tissue culture plates. They are fabricated by 
3D Biotek, LLC through a precision extrusion deposition (PED) type freeform fabrication 
process, with a layer pattern of a 0°/90° orientation and defined, controlled three-
dimensional porous structures of variable pore sizes ranging from 300 μm to 500 μm. 
The 3D InsertTM materials include both a biodegradable polymer: polycaprolactone 
(PCL), and a non-biodegradable polymer: polystyrene (PS), respectively. PCL has been 
extensively studied as a biodegradable scaffold material for bone tissue engineering 
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applications and PS is a transparent, non-cytotoxic material conventionally used in 
various two-dimensional cell culture vessels. A 14-day study using a rat osteoblast cell 
line was conducted comparing 3D Insert™ of PCL and PS with two-dimensional 
monolayer culturing, as well as the effect of varying pore size and relative enhancement 
over a two-dimensional monolayer control group. A fluorometric indicator of cell 
metabolic activity was performed to determine cell proliferative capacity along with ALP 
activity, a measure of osteoblast cell function. The ability to fabricate porous PCL and PS 
3D Insert™ using freeform fabrication system was demonstrated with accuracy and 
process repeatability for defined, controlled microstructures and physiologically relevant 
pore sizes. Biological characterization data of osteoblastic cell function are shown in 
Figure 6-1.  
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Figure 6-1: Comparison of alkaline phosphatase activity for PCL and PS 3D InsertTM 
with two-dimensional conventional monolayer culture 
For the same number of cells, the experimental data suggests that at certain time points, 
the precipitous decrease in fluorescent intensity in the case of two-dimensional 
monolayer culture is due to the over-confluence of cells on the two-dimensional surface 
in which case cells can no longer spread, undergo contact inhibition, and leads to gradual 
loss of viability. Cell functions in the 3D Inserts™, for both the PS and PCL samples are 
improved from two-dimensional monolayer culture. From proliferation studies, PS is 
observed to exhibit a steeper proliferation curve compared to PCL. For both 3D Inserts™, 
the smaller pore size of 300 um (samples 3050 in Figure 6-1) had a steeper proliferation 
curve compared to that of with the larger pore size of 500 um (samples 5050 in Figure 6-
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1). This may be attributed to larger pore sizes leading to lower seeding efficiency initially 
(as cells may fall through larger pores). The general trend of the graph of alkaline 
phosphatase activity (Figure 6-1) shows that the cell function is higher in the three-
dimensional case early on. This advantage conferred to the three-dimensional culture 
systems becomes even more significant at days 7 and 14 as cells grow on the three-
dimensional structure and the two-dimensional counterpart reaches overconfluence. 
6.1.2  Three-dimensional Tissue Constructs for Enhanced Hepatocyte Function 
Three-dimensional cell growth does not merely resemble the geometry of in vivo 
tissue, but is a basic requirement for the cells to retain their differentiated phenotype 
through cell-to-cell interactions as three-dimensional cellular aggregates. The aim of this 
3-day functional study is to evaluate the implications of a bioprinted three-dimensional 
structure on a measure of hepatocyte-specific function, namely urea synthesis. The 
experimental setup for this study involved one experimental test sample and one control. 
The experimental test sample was the bioprinting of a three-dimensional 
hepatocyte/alginate tissue construct. The control group selected is a two-dimensional 
hepatocellular monolayer with equivalent cell number as the test sample. In Figure 6-2, 
urea synthesis is quantitatively detected with a cell-based colorimetric assay, allowing 
comparison of time-dependent phenotype for bioprinted cell-encapsulated hepatocytes 
with controls cultured as a hepatocellular monolayer.  
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Figure 6-2: Results of 3-day urea synthesis study of bioprinted hepatocyte embedded 
alginate tissue constructs 
 
Cell medium is replenished for both the test sample and control once per day. Each data 
point constitutes an average of 5 samples taken at Days 1, 2, and 3 after bioprinting. This 
data suggests that a hepatocytes encapsulated in a three-dimensional alginate/hepatocyte 
tissue construct synthesizes a higher amount of urea than the same number of hepatocytes 
cultured as a two-dimensional hepatocyte cell monolayer. This difference is most striking 
on Day 1, where the three-dimensional tissue construct shows a marked urea 
concentration of 1.90 mg/mL compared to a two-dimensional hepatocyte cell monolayer 
urea concentration of 0.65 mg/mL. While the marked dropoff in urea synthesis at Day 3 
is typical of in vitro culture, the three-dimensional microenvironmental structure confers 
an ability for increased urea production relative to the two-dimensional monolayer case. 
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Therefore, this demonstrated that the bioprinting process for microencapsulation of 
hepatocytes in three-dimensional alginate tissue constructs is compatible with 
enhancement of hepatotocellular specific function compared to its two-dimensional 
counterpart. 
5.2 Effect of Material Properties on Liver Cell Metabolic Function 
Prior to drug perfusion flow cultures, experiments are conducted to first establish 
optimal experimental conditions for the drug metabolic response of hepatocytes 
encapsulated in a three-dimensional bulk alginate tissue constructs under bioprinted 
conditions and subsequent static culture. In the first set of experiments, the quantitative 
effect of alginate concentration in variable media volumes upon the drug metabolism of 
the HepG2 cells encapsulated in alginate bioprinted constructs is assessed. In the second 
set of experiments, the effect of cell type, cell confluency, cell seeding density, and media 
volume on drug metabolism is evaluated for HepG2 cells encapsulated in alginate 
bioprinted constructs.  
In the liver, cytochrome P450 enzyme complexes are the major players in the 
oxidative metabolism of a wide range of structurally diverse xenobiotics including drugs. 
Several model probe substrates for specific P450 enzymes have been identified that can 
produce highly fluorescent metabolites in aqueous solutions. The measurement of drug 
metabolism in this thesis are all based on the metabolic conversion of the drug 7-Ethoxy-
4-(trifluoromethyl)coumarin (EFC) to 7-Hydroxy-4-(trifluoromethyl)coumarin (HFC) by 
 109 
 
the enzyme 7-Ethoxycoumarin O-deethylase found in several P450 enzymes as shown in 
the metabolic reaction in Figure 6-3.  
 
Figure 6-3: EFC as a suitable fluorogenic substrate probe  
Although the P450 enzymes are heterogously expressed in the hepatocyte (e.g. O-
deethylation of EFC is known to occur in several different P450 enzymes), for CYP2B6 
activity, EFC has been demonstrated to have the best fluorescent probe properties with 
highest metabolic rates and lowest background fluorescence (Donato et al. 2004). 
In all experiments, drug metabolism by measuring fluorescent readings 
correlating with drug metabolite HFC concentrations. The fluorescent emission and 
excitation behavior of both drug reactant and metabolite are assessed and shown in 
Figure 6-4.  
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Figure 6-4: Emission and excitation wavelengths of EFC and HFC. 
 
Based on these results, we are able to optimally measure drug excitation and emission at 
360 nm and 520 nm, respectively, with the cytofluoremeter.  
 The quantitative effect of alginate concentration upon the drug metabolism of the 
HepG2 cells encapsulated in alginate bioprinted constructs is first studied. Each sample 
comprises of a bioprinted bulk HepG2-embedded construct. The results are tabulated 
below in Figure 6-5. 
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EFC Metabolism of HepG2 cells in Alginate 
Effect of alginate concentration and media volume
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.5%
1ml
1.5%
0.7ml
1.5%
0.4ml
1.5%
0.2ml
2.25%
1ml
2.25%
0.7ml
2.25%
0.4ml
2.25%
0.2ml
3.0%
1ml
3.0%
0.7ml
3.0%
0.4ml
3.0%
0.2ml
[H
FC
] u
M
2
3
4
5
6
7
8
22
 
Figure 6-5: Effect of alginate concentration and media volume on bioprinted HepG2-
embedded alginate constructs 
 
Since the cell concentration of encapsulated hepatocytes can vary over a wide range, the 
cell concentration would be expected to have a major influence on the metabolic activity 
of encapsulated hepatocytes, which are affected by influences like cell-cell contact or 
mass transfer limitation at higher concentrations. However, the study for the variation of 
alginate concentration (1.5%, 2.25%, 3.0% w/v) on drug metabolism does not 
demonstrate any effect on percentage of drug conversion. The explanation for this may be 
attributable to the small solute size (i.e. drug) which, as a virtue of its small molecular 
weight , increasing the amount of material (and therefore decreasing the amount and size 
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of micro-pore spaces between alginate chains for the drug to diffuse through) is not 
enough to hinder diffusion of such a small solute. Therefore, from the perspective of the 
drug particles, navigating through the 3.0% alginate is as easily accessible to the 
encapsulated cells as the 1.5% alginate. While this is the window for the material 
parameters that we studied since literature values for alginate are typically between 1.5-
3.0% as well as suitable for our biomanufacturing process, appreciable differences in 
drug conversion may be observed at lower or higher concentrations if such a study were 
conducted. The study for the variation of media volume on drug metabolism also does 
not show any differences on percentage of drug conversion. It should be clarified that the 
media volume did have an effect on the amount of drug being metabolized, however, not 
on the percentage of drug being metabolized. The reason is that the concentration of drug 
in all of the studies are kept constant. Therefore, for example, a volume of 0.2mL would 
have only one-fifth of the amount of drug solute in a volume of 1.0mL. Therefore, the 
media volume with 1.0mL will have higher HFC product because it had more EFC 
reactant to begin with. However, the drug conversion, i.e. the percentage of drug actually 
converted is the same for all media volumes studied, whether working at higher or lower 
media volumes. 
6.3 Effect of Cell Culture Conditions on Liver Cell Metabolic Function 
 In this set of experiments, the effect of various cell culture conditions (i.e. cell 
confluency, cell type, cell seeding density) on drug metabolism is evaluated for HepG2 
cells encapsulated in alginate bioprinted constructs. The nutrient media conditions are 
particularly essential in the culture of hepatocytes which are highly metabolic cells that 
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have high oxygen uptake rates compared to many other types of mammalian cells (Balis 
et al., 1999, Foy et al., 1994).  
 In conventional two-dimensional cell culture biology, confluency refers to the 
coverage or proliferation that the cells are allowed over or throughout the culture 
medium. Typically, after confluence is reached (i.e. all the available growth area is 
utilized and cells make close contact with one another), specific cells whose growth is 
sensitive to density limitations and subsequent contact inhibition will stop dividing. 
Therefore, maintaining a low cell density (e.g. 40-60% confluence helps to presernve the 
normal phenotype in cultures such as mouse fibroblasts, in which spontaneous 
transformants tend to overgrow at high cell densities (Todaro et al., 1963). However, a 
general trend observed for many cell types, e.g. hepatocytes and chondrocytes, is that 
cells permitted to aggregate in culture are more functional and longer survivability due to 
enhanced cell-cell interactions (Glicklis et al., 2000). Therefore, a prefatory study of cell 
confluency is conducted in which the experimental groups are categorized into 3 groups 
of increasing culture confluency before trypsinization and subsequent bioprinting and 
assay: confluence, 3-day confluence, and 5-day confluence. The results are shown in 
Figure 6-6 at an initial reactant concentration of 120 uM EFC and variable initial cell 
seeding densities.     
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Figure 6-6: Effect of cell confluency on 120 uM EFC metabolism 
This result indicates the 3-day confluent cells are most suitable for conducting short term 
drug metabolism studies.  
 In this thesis, immortalized hepatocytes are used in lieu of primary hepatocytes 
due to ease in handling, stable phenotype over time, and amenability to multiple 
generation of subcultures. Primary human hepatocytes represent the more pertinent 
model for short-term in vitro drug metabolism since they express higher levels of the 
P450 enzymes. However, as with other mammalian primary hepatocytes, they exhibit a 
limited growth activity and early phenotypic alterations. Hepatocyte cell lines, mainly 
originating from tumors (e.g. the hepatoblastoma HepG2), possess an indefinite capacity 
for proliferation (Castell et al., 2006). In the next set of studies, two human cell lines of 
 115 
 
immortalized hepatocytes are compared for their relative drug conversion capabilities as 
shown in Figure 6-7. 
 
Figure 6-7: Effect of cell type on 120 uM EFC metabolism 
HepG2 shows betters metabolic conversion compared to the HepG2/C3A subclone. 
This difference is even more pronounced for initial reactant concentrations of 30 uM 
EFC and 60 uM EFC, respectively, shown in Figure 6-8 and 6-9. 
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Figure 6-8: Effect of cell type on 60 uM EFC metabolism 
 
Figure 6-9: Effect of cell type on 30 uM EFC metabolism 
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6.4 Drug Perfusion Studies 
6.4.1 Structural Formability of Bioprinted Sinusoidal Liver Micro-pattern 
The ability to manufacture porous scaffold structures based on designed porosity, pore 
size, and pore interconnectivity in a reproducible, precise, and timely manner would be 
quite valuable for tissue engineering constructs. With the direct cell writing system, due 
to variable ambient conditions during the biopolymer deposition, there may exist slight 
differences between the designed construct pattern dimensions and the manufactured 
ones. In order to assess the reproducibility and detect variability of this biofabrication 
process for precise three-dimensional structural formability, a series of measurements are 
done on five different location of each tissue construct.  A live/dead assay was performed 
on representative roadwidths for each strut size specification with encapsulated live cells 
indicated as green in Figure 6-10: 
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(a) 150 um road widths 
 
(b) 250 um road widths 
 
(c) 400 um road widths 
Figure 6-10: Structural formability for design specifications 
The measurement data for 15 scaffolds (n=5 for each strut width design specification) 
and the solid model of the designed tissue construct are summarized in Table 6-1 
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Strut Width Design 
Specification 
Strut 
Width 
Pore size 
(μm) 
1A (250 um) 235±8 240±7 
2A (250 um) 240±4 241±5 
3A (250 um) 239±6 239±7 
4A (250 um) 242±5 252±3 
5A (250 um) 239±9 251±6 
1B (150 um) 158±5 251±6 
2B (150 um) 155±10 246±9 
3B (150 um) 149±6 248±11 
4B (150 um) 147±3 240±6 
5B (150 um) 157±7 248±11 
1C (400 um) 420±7 251±7 
2C (400 um) 417±7 253±9 
3C (400 um) 415±7 258±6 
4C (400 um) 409±7 252±8 
5C (400 um) 410±7 256±7 
Table 6-1. The strut width and pore size measurements of fifteen tissue constructs 
manufactured by direct cell writing 
Based on the measurements data given in Table 6-1, the average strut width for the 250 
um, 150 um, and 400 um strut width design specifications are 239 μm, 152 μm, and 411 
μm. The ± represents standard deviation of five different measurements of the constructs. 
This corresponds to an accuracy of 90% based for the designed strut widths. This data 
demonstrates a highly precise and reproducible biofabrication process typical of layered 
biomanufacturing techniques. 
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6.4.2 Drug Metabolic Function of Liver Micro-organ Under Continuous Perfusion 
Flow 
A study is conducted to see the effect of dynamic drug perfusion flow through an 
in vitro three-dimensional Microfluidic Microanalytical Micro-organ Device (3MD) on 
the metabolic drug conversion in bioprinted alginate-encapsulated HepG2 liver cells. The 
tissue constructs (n=8) are first bioprinted into specified sinusoidal geometry directly into 
the PDMS tissue chamber.  
 
Figure 6-11: Specified three-dimensional sinusoidal design pattern for bioprinted liver 
construct 
The controls (n=8) selected for the flow experiments are 1.) bioprinted three-dimensional 
static culture and 2.) two-dimensional monolayer in 24-well plate.  In the control groups, 
both cell viability via live/dead stain and drug metabolic conversion are assessed at 
approximately 4 hrs and 24 hrs after bioprinting. For the experimental flow group, the 
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bioprinted cells are permitted to “recover” from the bioprinting process for 24 hrs. This 
recovery phase maintains the tissue chamber under media flow for adequate nutrient 
delivery. After 24 hours of media infusion, media/drug is infused at a rapid enough rate 
to fully purge system of the original media volume as shown in Figure 6-12.  
  
 
Figure 6-12: A fully perfused tissue chamber with drug and nutrient media and clamping 
device to maintain leakage-free flow 
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The flow perfusion setup or micro-bioreactor with simultaneous pumping and withdrawal 
of drug/media is incubated under physiological conditions and shown in Figure 6-13 
below. 
  
 
Figure 6-13: Drug flow perfusion setup for parallelization study 
In order to ensure 4-hour residence time in the tissue chamber, the infusion flow rate is 
calculated and adjusted to 0.015 mL/hr. This flow rate is maintained for another 48 hours 
to purge tubing and collect adequate drug effluent volume in the withdrawal tube for 
cytofluoremeter sampling.  
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Figure 6-14: A fully perfused tissue chamber with drug/media 
Therefore, the fully perfused tissue chamber is a single micro-organ that is assayed for 
HFC drug metabolic conversion in Figure 6-14 with a drug residence time of 4 hours. 
The bioprinted three-dimensional static (n=4) is cultured in the incubator for an 
equivalent 4 hours. The bioprinted three-dimensional flow conditions confers an 
approximately 26% increase in HFC drug metabolic conversion as compared to the 
bioprinted three-dimensional static conditions in Figure 6-15.  
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Figure 6-15: Metabolic drug conversion of bioprinted three-dimensional tissue 
constructs under static versus dynamic flow conditions with 4 hr residence time in tissue 
chamber 
6.4 Summary of Key Results and Conclusions 
In this chapter, the liver micro-organ is characterized biologically for its suitability as an 
in vitro drug metabolism platform under continuous perfusion flow. Preliminary to 
conducting the drug perfusion flow studies, static culture experiments are carried out to 
1) validate the need for a three-dimensional microenvironment and 2) elicit the material 
parameters and nutrient media requirements favorable for optimal drug conversion. The 
rationale for a three-dimensional microenvironment is first tested, with enhanced 
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osteoblastic function exhibited on polystyrene scaffolds and liver-specific urea synthetic 
function exhibited in bioprinted tissue constructs. For drug metabolic function, the cell 
encapsulant material parameters varying alginate concentrations (1.5%, 2.25%, 3.0% 
w/v) on drug metabolism does not demonstrate any effect on the percentage of drug 
conversion. In a study of the extent of cell confluence on drug metabolism 3-day 
confluent cells are found to be most suitable for conducting short term drug metabolism 
studies. In a study of nutrient media requirements for bioprinted liver cell-embedded 
constructs, media volume did have an effect on the amount of drug being metabolized, 
however, not on the percentage of drug being metabolized. Finally, structural formability 
of sinusoidal patterned tissue constructs with the direct cell writing system was also 
assessed, demonstrating a highly precise and reproducible biofabrication process typical 
of layered biomanufacturing techniques. In the drug perfusion study, dynamic flow 
conditions for the bioprinted three-dimensional micro-organ device conferred an 
approximately 26% increase in HFC drug metabolic conversion as compared to the 
bioprinted three-dimensional static conditions, consistent with the that predicted from 
numerical methods and fundamental understanding of the liver microenvironment. 
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CHAPTER 7.  SUMMARY, CONCLUSION, AND RECOMMENDATIONS 
 
7.1 Summary of Research 
A specific targeted novel application of biomanufacturing approaches includes the 
development of an in vitro drug metabolism model. Such an in vitro drug metabolism 
model can be realistically and reliably implemented to predict human response to various 
drug administration and toxic chemical exposure for NASA’s interest of a flight-suitable 
drug metabolism platform in microgravity and planetary environments. A high-fidelity in 
vitro drug metabolism model is also important for the biopharmaceutical industry’s 
interest in drug and toxicology screening prior to the pursuance of clinical drug trials. 
This research details the fabrication process development and adaptation of microfluidic 
devices for the creation of a pharmacokinetic model involving the combinatorial setup of 
an automated syringe-based, layered direct cell writing (DCW) bioprinting process with 
soft lithographic micro-patterning techniques to fabricate a microscale in vitro device 
housing a chamber of bioprinted three-dimensional micro-organ that biomimics the cell’s 
natural microenvironment for enhanced performance and functionality. By designing and 
biofabricating various microscale three-dimensional physiological tissue engineered 
constructs within tissue chambers on a microfluidic chip, one can selectively model an 
interconnected network of differentiated mammalian tissues for a number of applications, 
among them pharmaceutical screening for drug efficacy and toxicity along with 
apprehension of the disposition and metabolic profile of a candidate drug. This thesis 
addresses issues related to the development and implementation of a unique bioprinting 
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process for freeform biofabrication of three-dimensional cell-encapsulated hydrogel-
based tissue constructs with defined patterns, the direct integration onto a microfluidic 
device for drug metabolism study, and the underlying engineering science behind the 
flow pattern design and hydrodynamic conditions (e.g. wall shear stress) for perfusion of 
the three-dimensional microscale tissue chamber for drug metabolism study. To this end, 
a prototype three-dimensional microfluidic tissue chamber embedded with cells 
encapsulated within a hydrogel matrix construct is bioprinted as a physiological in vitro 
model for drug metabolic investigation. 
7.2 Conclusion and Remarks 
For millions of years, cells have been thought of as nature’s building blocks that 
assemble to make us what we are. Broadly speaking, biomanufacturing uses cells and 
other bioactive factors as nature’s basic building blocks from which biological models, 
systems, devices, and products are assembled. Biomanufacturing techniques encompass a 
broad range of physical, chemical, biological, and/or engineering processes, with various 
applications in tissue science and engineering, disease pathogeneses and drug 
pharmacokinetic studies, biochips and biosensors, cell printing, patterning, and assembly, 
and emerging organ printing. Many different cell manipulation techniques have been 
explored, such as syringe-based cell deposition for tissue constructs; bioassembly tools; 
rapid prototyping of hydrogel structures; inkjet-based cell printing; laser direct writing of 
mammalian cells and bacteria; microcontact printing; cell manipulation by mechanical, 
optical, electrical, magnetic, ultrasound, and ionic methods for microfluidics; and cell 
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patterning by photo- or electroetching, and soft lithography. As an interdisciplinary 
research area, tissue science and engineering will increasingly rely on biomanufacturing 
technologies to help establish a new knowledge base in applications including, as 
presented in this thesis, in vitro drug metabolism models. 
7.3 Research Contributions  
My research science and engineering contributions are as follows: 
1)  Developed the direct cell writing system to biofabricate three-dimensional 
patterned tissue constructs for direct integration on a microfluidic substrate to 
enable novel creation of a micro-organ device for in vitro drug metabolism study. 
2) Studied bioprinting process parameters to optimize cell viability in drug perfusion 
studies. 
3) Studied material/culture conditions to optimize drug metabolic function in drug 
perfusion studies. 
4) Developed a framework of an engineering analysis model to predict effect of liver 
flow pattern design/conditions on drug metabolism. 
7.4 Future Work and Recommendations 
7.4.1 Novel Temperature-Controlled Printing System for the Solid Freeform 
Fabrication of Cell-Laden Matrigel Constructs 
Matrigel is a promising natural biomaterial that is currently being studied as a basis for 
pharmacokinetic models. Matrigel’s composition of natural biopolymers mimics in vivo 
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microenvironments, facilitating better cell viability, differentiation, and function in a cell-
embedded tissue construct. However, Matrigel’s use in solid freeform fabrication 
techniques, the sequential delivery of cell-seeded biomaterials to specified points in 
space, has been limited by its unique thermo-physical properties as it is a fluid that 
liquifies below 4oC and constitutes a cross-linked gel at physiological temperature of 
37oC. Current biofabrication systems such as the direct cell writing system cannot be 
trivially adapted to bioprint Matrigel, as the material occludes the bioprinting apparatus, 
which operates at room temperature. To overcome these current obstacles in the 
biofabrication of Matrigel constructs, the development of a miniaturized temperature-
controlled printing system has been proposed with the ability to maintain a suitable 
temperature at or below 4oC and create cell-laden patterned Matrigel constructs. During 
an early research and development phase, temperature-controlled enclosure has already 
been produced along with a Matrigel delivery system, and an integrated and automated 
motion system. Currently, the prototype is being tested by printing rat tail tendon 
collagen type I as a Matrigel model material, as the high cost of Matrigel limits its 
availability for testing. Successful patterned constructs have been created, with 
significant increase in printing ability in the sample maintained at approximately 4oC as 
compared to the room temperature control.  
7.4.2 Direct Cell Writing Into Multichambers for In Vitro Radiation Model 
An ongoing extension of the collaboration with NASA is the creation of a multichamber, 
multicellular in vitro model for studying drug radioprotection. Firstly, the direct cell 
writing system is implemented to bioprint patterned three-dimensional constructs of 
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viable epithelial cells. The two distinct cell types, hepatocytes (HepG2) and melanoma 
cells (M10) will be encapsulated in Matrigel and printed via a temperature/motion 
controlled direct cell writing system. Next, the dual micro-organ is assembled and sealed 
to complete the microfluidic circuit. The serially connected M10 and HepG2 tissue 
chambers are perfused with media (for nutrients) and anti-radiation pro-drug 
Amiphostine (for select samples) over the bioprinted constructs. To assess the protective 
efficacy of anti-radiation drug on irradiated cells, the tissue constructs will be exposed to 
a low dose of Gamma Radiation after pro-drug treatment. Drug effectiveness can be 
analyzed via DNA damage quantified by micronuclei staining. The hypothesis is that in 
comparing the extent of pro-drug to active drug conversion, HepG2 cells express a much 
lower capacity than M10 to convert the pro-drug Amiphostaine to its active form. In the 
dual micro-organ, drug perfuses the M10 construct, is converted to active form, and then 
fed downstream to exert an effect on the HepG2 target construct. 
7.4.3 Tissue Integrated Microbioreactor-on-a-Chip to Enable In Vitro 
Nanotoxicity Evaluation 
A proposed future plan is to develop an optical measurement technique to directly 
identify and evaluate novel nanoprobes designed to target cells of an in vitro tissue-
engineered model. In vitro cell model systems are versatile instruments with great 
potential to advance both toxicological and tissue engineering research by simulating 
signaling and mechanistic phenomena under physiological conditions. Such models are 
particularly attractive as tremendous positive impacts of nanotechnology in medicine 
become ubiquitous, and limited data on the potential risks of nano-sized particles to 
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human health and the environment emerge. Currently, however, robust quantification, 
evaluation, prediction, and verification of the biological fate, distribution, and risks of 
nanoparticles in vivo are lacking. In the proposed work, a 3D tissue-based model subject 
to physiological perfusion flow will enable broad application as an in vitro testbed for 
nanoparticle toxicity evaluation on tissues under in vivo–like conditions. Specifically, the 
convergence of several key enabling technologies in the fields of solid freeform 
fabrication (SFF) and microfabrication will feasibly lead to a complex and 
physiologically pertinent 3D tissue integrated microbioreactor-on-a-chip model amenable 
to long-term nanotoxicological study. To illustrate this model’s applicability in 
nanotoxicology, dynamical optical imaging techniques will be applied to a fabricated 
microbioreactor-on-a-chip tissue testbed using novel quantum dot multimodal imaging 
probes called upconverting nanoparticles (UCNPs).  
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APPENDICES 
The direct cell writing protocol presented below is established for a reliable, high-
throughput drug screening model.  
A. Cell-alginate biopolymer solution preparation:  
1. To prepare the pre-polymer solution, dissolve medium viscosity sodium alginate 
powder in DI water as a 3.0% (w/v) solution. 
2. Mix with magnetic stir bar overnight. 
3. Sterilize sodium alginate solution by serial filtration using 0.85 μm, 0.45 μm, and 
0.20 μm syringe filters. 
4. To prepare the ionic cross-linking solution, dissolve calcium chloride in DI water 
as a 5.0% (w/v) solution. 
5. Prepare HepG2 liver cells by culturing and maintaining in Dulbecco’s Modified 
Eagle’s Medium (DMEM), supplemented with 10% (w/v) fetal bovine serum, and 
maintained in the incubator at 5% CO2 and 37°C. 
6. Centrifuge prepared HepG2 cell suspension (e.g. 8,000 × g for 5 min). 
7. Resuspend the cells in sodium alginate pre-polymer solution with gentle pipetting. 
B.  Preparation of microfluidic components for bioprinting: 
1. Wash glass cover slide successively x 3 with acetone, ethanol, and DI water.  
2. Leave recently baked PDMS substrate as is (i.e. without washing). 
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C.  Plasma treatment of microfluidic components for bioprinting: 
1. Use tweezers to gently place clean glass cover slide and PDMS substrate onto 
quartz plate inside plasma chamber. 
2. Turn on vacuum of plasma chamber for 1 minute. 
3. Expose glass cover slide and PDMS substrate to RF plasma for 30 seconds. 
D. Direct cell writing into tissue chamber of microfluidic device: 
1) Take plasma-treated PDMS layer to the printing system.   
2) Align tissue chamber and height. 
3) Print cell/alginate suspension into the tissue chamber using defined toolpath. 
4) Specify and adjust the printing process parameters according the design 
specifications. 
5) CaCl2 crosslinking agent dispensed at regular intervals using second pneumatic 
nozzle. 
6) Affix glass layer to the PDMS layer to seal the system. 
7) Place chips in sterile container / seal container. 
E. Adaptation of microprinted tissue construct for pharmacokinetic study: 
1) Take sealed container to hood and place into chip holder/clamps. 
2) Attach to syringe pump using tubing and Nanoports. 
3) Place inside incubator. 
F. Assessment of cell viability for three-dimensional cell-alginate constructs: 
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1)  Add 1mL of Live/Dead assay to each sample. 
2) Incubate for 45 minutes. 
3)  View under a Leica fluorescence microscope at 40X magnification 
4) In order to quantify the cell viability and assign a cell viability percentage 
throughout the time course study, each sample is visualized and a live-dead cell 
count performed at five different locations (three peripheral, two central) for the 
bulk sample.  
G.  Cell counting in three-dimensional cell-alginate constructs using microplate 
reader: 
1)  Use hemocytometer to obtain the number of cells/ml in cell solution. 
2)  Cell solutions are made at different concentrations ranging from 250,000 cells/ml 
to 2,000,000 cells/ml at 250,000 cells/ml intervals. 
3) X volume of Alamar Blue is added to Y volume of each cell solution 
concentration in step (2) to give a total volume Z. 
4)  Each Z volume of different cell concentration/Alamar Blue solution is placed into 
6 wells in a 6x8 well plate. 
5)  The well plate is placed in the cytofluorimeter and a reading is given out for each 
well plate. Measure concentration of reduced Alamar Blue solution using a 
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microplate reader with an excitation filter wavelength of 535 nm and an emission 
filter wavelength of 595 nm. 
6)  A curve is obtained presenting the number of cells versus the microplate reading. 
7)  Scaffold is immersed in a known cell solution volume for 1 hour in incubator. 
8)  Scaffold is removed from cell solution and kept in a new culture dish. 
9)  Alamar Blue (fluorescence dye) is added at volume A (depending on scaffold 
size) to the cells seeded scaffold in the new culture dish and kept in the incubator 
for 3 hours.  This step allows the cells in the printed construct to metabolize the 
Alamar Blue. 
10) The Alamar Blue solution is removed from the scaffold and the W volume is 
divided into 6 wells in a 6x8 well plate.  Each well contains Z ml of the Almar 
Blue solution. 
11) Fresh medium is added to the scaffold and is replaced back in the incubator 
12) The well plate is placed in the microplate reader and a reading is given out for 
each well plate.  
13) The data from step (6) is used to obtain the number of cells in step (12). Step (8) 
to (13) could be repeated over a number of days to obtain the proliferation of cells 
in the scaffold over a couple of days. 
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H. Assessment of liver cell-specific urea synthesis function: 
1) 1 mL of QuantiChrome Urea Assay (BioAssay Systems, Hayward, CA) solution, 
a fluorometric indicator of liver cell urea synthetic activity, is added to each 
printed sample. 
2) Replenish media with assay daily. 
3) Measure concentration of urea using a microplate reader with an absorbance filter 
wavelength of 520 nm. 
I. Drug Metabolism Protocol for Liver Cells: 
1)  Drug substrate EFC = 7-ethoxy-4-trifluoromethyl coumarin 25 mg of drug comes 
in a glass amber vial and should be reconstituted in 9.68ml of DMSO to create a 
10mM stock solution of EFC.  
2)  Drug product HFC (for standard curve) = 7-hydroxy-4-trifluoromethyl coumarin 
100 mg of drug comes in a glass amber vial and is reconstituted in 43.5 ml of 
DMSO to create a 10 mM stock solution of HFC. 
3) Carry out formation of EFC and HFC stock solutions in the laminar flow hood 
using good sterile technique and sterile DMSO. Store stock solutions dessicated in 
the refrigerator. 
4)  Once the drug and standard stock solutions have been made, they can be diluted 
to the desired working concentration in cell culture media just prior to an 
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experiment. 120 μM EFC has been found to work quite well for drug metabolism 
studies in the HepG2 cells. 
5)  To create 10 ml of a 120 μM EFC test solution: 
Dilute 120 μL of the 10 mM EFC stock solution into 9.88 ml of HepG2 medium 
and mix well. 
6)  To create 5 ml of HFC standard solutions ranging from 0.1 – 64 μM: 
Dilute 64 μL of the 10 mM HFC stock solution into 9.936 mL of HepG2 medium 
containing 120 μM EFC. 
7)  Serially dilute the 64 μM standard to achieve the desired standards. For example, 
add 5 ml of 64 μM HFC solution to 5 ml of 120 μM EFC test solution and mix 
well. This will be 32 μM HFC standard.  Then add 5 ml of the 3 μM HFC 
standard to 5 ml of 120 μM EFC test solution etc. until 0.125 μM HFC standard is 
reached. Use the 120 μM EFC test solution as the “zero” HFC standard. 
8)  To start a metabolism experiment: 
Remove medium covering test cells.  Replace with desired amount of 120 μM 
EFC test solution. 
8) Measure concentration of urea using a microplate reader with an excitation filter 
wavelength of 360 nm and an emission filter wavelength of 520 nm. 
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